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This report was prepared at the direction of John M. Douglas, Jr., M.D., Director, Division 
of STD Prevention, NCHSTP, CDC. It summarizes the available literature on expedited 
partner therapy (EPT) for the management of the partners of persons with STD and 
interprets the results.  It also incorporates perspectives gained from two expert 
consultations, one that predominantly addressed the scientific evidence related to EPT and a 
second that emphasized operational issues that will affect implementation of EPT.  The 
report serves as background on EPT and provides the evidence in support of anticipated 
guidelines for the selective use of EPT. It is intended as a reference document for use by 
CDC and by public health agencies, other organizations, interested individuals, and other 
partners in the public and private sector. 
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Expedited partner therapy (EPT) is the practice of treating the sex partners of persons with 
sexually transmitted diseases (STD) without an intervening medical evaluation or 
professional prevention counseling. The usual implementation of EPT is through patient-
delivered partner therapy (PDPT), although other methods may be employed.  The available 
literature and selected unpublished studies were systematically reviewed, and this report 
provides background for the development of guidance on use of EPT as an option for 
partner management for selected STDs and patients. 
Evidence 
For STDs other than syphilis, partner management based on patient referral or provider 
referral has had only modest success in assuring partner treatment, largely attributable to 
limitations of available financial and personnel resources.  EPT is believed to have been 
widely employed in women with trichomoniasis.  Recent surveys document occasional use 
by many primary care providers in the management of patients with gonorrhea and 
chlamydial infection, and consistent use by a few.  A retrospective case control study and 
two process-oriented analyses suggested that EPT holds promise as a partner management 
option. These studies contributed to CDC decisions to fund 4 randomized controlled trials 
(RCTs) designed to compare EPT with standard partner management approaches in men 
and women with gonorrhea, chlamydial infection, or trichomoniasis; and to assess 
behavioral predictors of treatment and reinfection. 
Persistent or Recurrent Infection 
The first RCT of EPT followed 1,787 women in 6 cities after treatment for chlamydial 
infection. Recurrent infection was documented at follow-up visits 1 months and 4 months 
later in 12% of women randomized to EPT and 15% of those managed by patient referral 
(odds ratio [OR] 0.80, 95% confidence interval [CI] 0.62-1.05).  The second RCT enrolled 
2,751 men and women with gonorrhea or chlamydial infection from both public and private 
care settings in a single metropolitan area.  Persistent or recurrent infection with either 
disease was found in 9.9% of subjects randomized to EPT and 13.0% of those who had 
standard patient-referral or provider-referral of their partners (OR 0.76, 95% CI 0.59-0.98).  
EPT was more effective in preventing gonorrhea at follow-up (OR 0.32, 95% CI 0.13-0.77) 
than chlamydial infection (OR 0.82, 95% CI 0.62-1.07).  Chlamydial infection was present 
at follow-up in 7.6% of women who denied all sex since treatment, suggesting that a higher 
than expected rate of treatment failure accounted for some infections at follow-up.  In the 
third available RCT, 977 men with symptomatic urethritis (principally gonorrhea and 
chlamydial infection) were randomized to EPT, patient referral, or patient referral enhanced 
by written education materials.  Follow-up testing for gonorrhea and chlamydial infection 
4-8 weeks later was accomplished in 37.5% of patients. Persistent or recurrent infection 
was found in 43% of subjects in the patient referral group (referent), 14% of men 
randomized to enhanced patient referral (OR 0.22, 95% CI 0.11-0.44, P<0.001), and 23% of 
men randomized to EPT (OR 0.38, 95% CI 0.19-0.74, P<0.001).  For trichomoniasis, in an 
as yet unpublished RCT of 463 women randomized to the same interventions as the male 
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urethritis trial, with 80% follow-up, the prevalences of infection 3-7 weeks later were not 
significantly different for patient referral (6%), enhanced patient referral (9%), or EPT 
(9%). 
Behavioral Outcomes 
The 4 available RCTs evaluated the association of EPT with index cases’ reports of success 
in partner notification, confidence that their partners were treated, and sexual behaviors 
likely to predict reinfection. In 2 trials that enrolled male index cases, men randomized to 
EPT were equally or more likely to notify their partners than those randomized to the 
control strategies. Female index cases with chlamydial infection or gonorrhea who were 
randomized to EPT had either equivalent success or enhanced success in notifying partners 
compared with women randomized to standard partner management.  In all 3 trials of 
gonorrhea or chlamydial infection, EPT was associated with at least equivalent and 
typically increased confidence by both male and female index cases that their partners had 
received treatment, including direct observation that their partners took medication.  Two 
trials that addressed both gonorrhea and chlamydial infection found EPT to be associated 
with significantly reduced rates of sex with untreated partners at follow-up.  The 
trichomoniasis trial showed general equivalence of EPT with desirable behavioral outcomes 
compared with standard patient referral.  
Cost Effectiveness 
Preliminary economic analyses suggest that EPT is a cost-saving and cost effective partner 
management strategy. 
Limitations 
The data available to support EPT for chlamydial infection were derived in larger and 
geographically more diverse samples of patients than those for gonorrhea.  Nevertheless, 
the evidence in favor of EPT, as measured by the rate of persistent or recurrent infection at 
follow-up, is stronger for gonorrhea than for chlamydial infection, perhaps due to a higher 
than expected rate of persistent chlamydial infection in women.  This finding confounds the 
assessment of EPT in women with chlamydial infection.  Assuring the treatment of infected 
men’s female partners is a high priority to prevent ongoing transmission and community 
spread. 
As for all RCTs, the extent to which the results of the available trials can be safely 
generalized to other populations and settings is not certain.  Owing to modest sample sizes 
in some disease-specific patient groups, and varying effect sizes, not all outcomes of 
interest have been shown to be statistically significant.  For example, further data are 
desirable on the use of EPT in male index cases.  The available data do not support the 
routine use of EPT in the management of trichomoniasis, and no published data support the 
use of EPT for chlamydial infection or gonorrhea in men who have sex with men (MSM).  
Although substantial numbers of adolescents were included in the available trials, there is 
little experience in patients <18 years old.   
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Issues in Implementation of EPT 
Among several pragmatic issues that will influence implementation of EPT as an STD 
prevention strategy, a dominant one is the possibility of undetected STD in partners.  The 
potential for undiagnosed pelvic inflammatory disease (PID) is of concern when EPT is 
used to treat the female partners of men with gonorrhea or chlamydial infection.  Therefore, 
EPT intended for female partners should be accompanied by warnings about the symptoms 
of PID and advice that women seek medical attention in addition to accepting treatment.  
Undiagnosed gonorrhea and chlamydial infection are common in the partners of women 
with trichomoniasis, and undiagnosed HIV infection and other morbidities have been found 
in many partners of STD-infected MSM. 
The legality of EPT is uncertain in some states and overt statutory impediments exist in 
others; the practice is clearly legal only in a few states.  The medicolegal ramifications may 
be uncertain in the event of adverse outcomes in the recipients of EPT.  Other barriers 
include direct and indirect costs, including limitations on third-party insurance coverage; 
missed opportunities for prevention counseling of partners; risks of allergic reactions and 
other adverse drug effects; administrative barriers; privacy issues; and the attitudes and 
beliefs of health care providers and agencies about the practice. 
Conclusions 
Both clinical and behavioral outcomes of the available studies indicate that EPT is a useful 
option to facilitate partner management among heterosexual men and women with 
chlamydial infection or gonorrhea.  The evidence indicates that EPT should be available to 
clinicians as an option for partner management, although ongoing evaluation will be needed 
to define when and how EPT can be best utilized.  EPT represents an additional strategy for 
partner management that does not replace other strategies, such as standard patient referral 
or provider-assisted referral, when available.  Along with medication, EPT should be 
accompanied by information that advises recipients to seek personal health care in addition 
to EPT. This is particularly important when EPT is provided to male patients for their 
female partners, and for male partners with symptoms.  Existing data suggest that EPT has 
a limited role in partner management for trichomoniasis.  No data support its use in the 
routine management of syphilis, and there is no experience with EPT for gonorrhea or 




Assuring treatment of infected persons’ sex partners has been a central component of 
prevention and control of bacterial STDs in the United States for six decades, since the 
concept was introduced in the United States by Thomas Parran and systematic efforts were 
implemented for the prevention of syphilis under Parran’s leadership of the U.S. Public 
Health Service in the 1940s.1  In general, treatment has been recommended for all partners 
sexually exposed to the infected index case within a specified time interval in order to 
prevent morbidity in the partners and curtail transmission.  Usually treatment was preceded 
by clinical evaluation, diagnostic testing, and education or formal counseling, and 
attendance at traditional clinical facilities was required.  Initially developed as a strategy for 
control of syphilis, such partner management came to be widely recommended for 
gonorrhea, chlamydial infection and, most recently, human immunodeficiency virus (HIV) 
infection.2,3 
Several strategies have been employed to facilitate clinical assessment and treatment of 
partners, as indicated in the Centers for Disease Control and Prevention’s Program 
Operations Guidelines.2 With provider referral, partners are directly contacted, usually by 
telephone or in person, by the index patient’s health care provider or by a disease 
intervention specialist (DIS) or other outreach worker on behalf of the provider.  Under 
patient referral, also called self referral, the index patient assumes primary responsibility to 
notify and refer his or her partners at risk.  These approaches may be combined.  For 
example, conditional referral, also called contract referral, describes patient referral 
supplemented by provider referral, such as a telephone reminder, for partners who do not 
respond within a specified time.  The term dual referral also has been used, particularly in 
the context of HIV partner management, to describe joint referral by the patient and a 
public health professional.3  Patient referral also can be supplemented by various 
mechanisms to assist the index patient in notifying his or her partners; for example, card 
referral means providing patients with appointment cards to deliver to partners. 
Despite extensive use, the contribution of partner management to overall STD prevention 
and control has been difficult to ascertain.  Success has been evaluated largely by analysis 
of process indicators, such as numbers of partners elicited and the number brought to 
treatment.  By these measures, provider referral strategies generally have been most 
effective.4-6  Provider referral is widely considered to have contributed significantly to 
control of syphilis, with a 1990s trial providing estimates of process effectiveness,7 but the 
efficacy of traditional partner management in assuring treatment of the partners of persons 
with gonorrhea or chlamydial infection remains problematical and their contribution to 
prevention and control uncertain.  Social network approaches for management of the 
partners of persons with syphilis or HIV infection have shown substantial promise in 
retrospective evaluations,8,9 but have not been studied for chlamydial infection, and may be 
too costly for routine use in most settings.  A single prospective evaluation of network 
techniques to enhance interviews and analyze data uncovered more syphilis cases than 
would have resulted from contacting only the sex partners of infected persons.10 
Most STD cases in the United States are diagnosed and treated in the private sector by 
primary care providers,11 but the available data on partner management are dominated by 
analyses in patients attending STD clinics or other public health clinics who often may not 
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be representative of most infected persons.  Except for syphilis, most health departments 
make little direct effort in partner management for persons with STDs treated in the private 
sector.12,13 The Institute of Medicine described STD partner management in the United 
States as inadequate, inefficient, and in need of redesign.14 
Anecdotal reports have long suggested that some clinicians selectively arrange for 
treatment of partners without referral or examination, typically by providing the index 
patient medication for his or her partner(s) or by writing a prescription to be delivered by 
the patient to the partner.  This practice is generally believed to have been particularly 
widely used for the treatment of the male partners of women with vaginal trichomoniasis.* 
Nevertheless, public health and prevention experts have typically insisted that treatment for 
partners of persons with gonorrhea, chlamydial infection or syphilis be administered only 
through direct clinical intervention. However, as the inadequacy of resources for provider 
referral and the modest success rate of patient referral in assuring notification and treatment 
of partners became apparent, streamlined approaches to partner management became the 
subject of increasing attention. 
This document reviews the evidence for use of expedited partner therapy (EPT), defined as 
treatment of partners without an intervening personal assessment by a health care provider.  
EPT may be implemented by any of several methods.  The usual method in many settings, 
and the one used predominantly to date, is patient-delivered partner therapy (PDPT), 
wherein clinicians provide their patients with drugs intended for the partners, prescribe 
extra doses of medication in the index patients’ names, or write prescriptions in the 
partners’ names.  Other potential means to achieve EPT include non-prescriptive 
arrangements with cooperating pharmacies, retrieval of medication by partners at public 
health clinics or other venues, or delivery of medication to partners in non-clinical settings 
by public health workers. 
* There are several possible reasons that the practice gained currency for trichomoniasis in particular. 
For many years trichomoniasis probably was not widely understood by many clinicians to be an 
STD, despite the conflict of that perception with the practice itself. Until the 1980s, gonorrhea 
typically required penicillin by injection and chlamydial infection was virtually unknown, so that 
trichomoniasis was the only commonly diagnosed STD that could be managed with single doses or 
short courses of oral antibiotic. Further, some clinicians may have believed that local or state health 





Traditional Partner Management 
To estimate the scope of attempted provider referral for common STDs by public health 
departments, Golden et al. surveyed 78 metropolitan health departments that collectively 
represented the 50 cities in the United States with the highest rates of at least one reportable 
bacterial STD (gonorrhea, chlamydial infection, syphilis) and the 50 metropolitan areas 
with the highest reported rates of AIDS.12,13  Sixty health departments (77%) submitted 
usable responses.  Of 8,492 cases of infectious syphilis reported to these health 
departments, in 7,583 cases (89%) public health authorities attempted to assure treatment of 
the patients’ sex partners. By contrast, the responding health departments attempted to 
identify and contact the partners of 17% of 139,287 reported cases of gonorrhea and 12% of 
228,210 persons with chlamydial infection.  When partner management was attempted for 
persons with gonorrhea or chlamydial infection, patient referral was the predominant model 
employed.  Forty-one health departments (68%) made no attempt to notify or contact the 
partners of patients treated for gonorrhea outside public health clinics, and 46 (77%) made 
no such attempt for the partners of persons with chlamydial infection.  The survey 
respondents cited lack of sufficient personnel and other resources as the dominant reason 
for low partner management coverage.12 
Most health care providers advise their patients with STD to notify their sex partners.  St. 
Lawrence et al. reported on the practices of a national probability sample of 4,223 
physicians in 5 specialties that report most STD morbidity in the United States (general or 
family practice, internal medicine, pediatrics, gynecology-obstetrics, emergency 
medicine).15  Eighty-eight percent of the respondents were in private practice and the 
survey had a 70% response rate. Almost 82% of respondents reported that they advised 
their infected patients to notify partners of exposure to gonorrhea or chlamydial infection 
and 9-11% collected partner information to send to a health department; only 4% attempted 
provider referral.  In another analysis of the same national probability sample, Hogben et 
al.16 found that most physicians in the U.S. were willing to report STD cases to their local 
health departments, but most respondents believed that provider referral is no more useful 
than patient referral in assuring partner treatment and were less supportive of provider 
referral by health departments than of other partner management strategies.  Among 150 
private sector providers in King County, Washington who had reported >1 case of 
chlamydial infection in the preceding year, 135 (90%) said they told their patients that their 
sex partners required treatment, and 72 (95%) of 76 patients acknowledged that they had 
been so informed.17  Twenty-six providers (17%) were confident that all partners at risk had 
been treated. 
Thus, patient referral is the dominant mechanism employed in the U.S. to assure treatment 
of the partners of persons with chlamydial infection or gonorrhea.  The proportion of 
partners who actually receive treatment or other direct clinical services is difficult to 
ascertain. Table 1 summarizes the results of 7 studies conducted in the United States and 
western Europe that reported the success of various patient referral strategies conducted by 
public health personnel to achieve treatment of partners exposed to gonorrhea or chlamydial 
infection.18-24  One study reported that 29% of partners were successfully treated; the 
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remaining studies reported success rates from 49% to 59%.  The proportion of partners who 
respond to patient referral as practiced by most providers, without the involvement of 
public health personnel, is unknown.  However, the available data suggest that roughly half 
of all partners of persons with gonorrhea or chlamydial infection receive treatment.  
Expedited Partner Therapy 
Emerging data indicate that many providers in the United States selectively employ EPT for 
gonorrhea and chlamydial infection and that some do so routinely.  Hogben et al.25 analyzed 
the responses of the national sample of physicians described above15 to questions about the 
providers’ partner management practices (Figure 1).  Among 2,538 physicians who 
reported treating at least one patient for chlamydial infection in the preceding 12 months, 
56% had managed at least one partner by PDPT and 15% “usually” or “always” did so.  
The results were similar for gonorrhea, with 50% of providers reporting use of PDPT and 
11% reporting PDPT as their usual or universal approach to partner management.  The 
investigators estimated that PDPT had been employed in the management of 9% to 15% of 
the respondents’ patients with gonorrhea and 13% to 20% of those with chlamydial 
infection. 
Four geographically limited surveys also have addressed the practice of EPT.  Among 111 
Connecticut and Rhode Island physicians, 48% indicated favorable attitudes toward PDPT, 
50% had employed the practice, and 6% reported using PDPT “frequently”.26  Of 150 
providers surveyed in King County, Washington, 57% had employed EPT for chlamydial 
infection in the preceding year and 21% reported doing so at least half the time, although 
only 5% of the providers had done so for their most recently diagnosed cases.17  In a 
stratified random sample of 708 physicians and 805 nurse practitioners in California 
undertaken soon after legislation was adopted to legalize EPT for chlamydial infection, 
EPT was reported substantially more frequently than in the preceding studies; about half the 
respondents reported “usually” or “always” using EPT for their patients with chlamydial 
infection, primarily by providing index patients with prescriptions for their partners.27 
Finally, according to preliminary analysis of a survey of providers in New York City,28 
approximately half the respondents had ever used PDPT and 27% reported doing so 
“frequently.” In the New York survey, an atypically high proportion of providers (24%) 
reported that they directly contacted their patients’ partners (provider referral).28 
Collectively, the national survey and two of the regional ones suggest that roughly half of 
U.S. clinicians who treat STD cases use EPT selectively and that 5% to 10% do so 
frequently or as their standard approach to partner management.  EPT may be used more 
frequently in California than elsewhere, perhaps because the survey was conducted amid 
publicity about recent legalization of the practice for chlamydial infection.  New York City 
providers apparently use EPT more frequently than in most regions but less frequently than 
those in California. 
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RESEARCH IN EXPEDITED PARTNER THERAPY 
Preliminary Studies 
The first published study with data on EPT was a retrospective analysis of the prevalence of 
Chlamydia trachomatis within 12 weeks of treatment for chlamydial infection in Swedish 
women (Figure 2).29  Among 372 women in whom no effort was made to identify or treat 
partners, 38 (10.2%) had recurrent or persistent infection.  Infection was present in 84 
(8.4%) of 997 women told to refer their partners without further follow-up (patient referral), 
and in 31 (4.5%) of 645 women who were told to refer partners followed by reminders 
when partners failed to appear (conditional referral).  Among 167 women managed with 
PDPT, 3 (1.8%) had persistent or recurrent infection.  Although the partner management 
strategies were not randomly assigned and provider selection probably influenced the 
results, this report offered the first evidence that EPT might hold promise for partner 
management in women with chlamydial infection.  
Kissinger et al. analyzed reinfection rates in 256 women with chlamydial infection treated 
at an urban STD clinic, of whom 178 were re-tested a mean of 17.7 + 7.7 months later.30 
The annualized rate of reinfection was 12% among 43 women managed with PDPT, 
compared with 22% of 135 managed by card-enhanced patient referral (odds ratio [OR] 
0.37, 95% confidence interval [CI] 0.15-0.97, P <0.05).  In Uganda, Nuwaha et al. 
undertook a randomized controlled trial (RCT) of PDPT compared with card-enhanced 
patient referral in STD clinic patients given syndromic management for urethral or vaginal 
discharge.31  After 2 weeks follow-up, index patients managed with PDPT reported that 176 
(74%) of 237 identified partners had received treatment, whereas 79 (34%) of the 234 
partners identified by control patients attended the clinic to be treated.  Although the 
investigators reported these outcomes as significant in favor of PDPT (OR 2.44, 95% CI 
1.95-3.07), the differences in ascertainment of partner therapy—index case report vs. 
partner attendance at a clinic—make comparison difficult and the validity of the outcome 
uncertain. 
Randomized Controlled Trials: Biomedical Outcomes 
Four RCTs comparing EPT with traditional partner referral strategies, funded wholly or in 
part by CDC, have been conducted in the United States among patients with gonorrhea, 
chlamydial infection or trichomoniasis.32-35  The prevalences of persistent or recurrent 
infection in index cases at follow-up are summarized in Table 2.  
Multicenter Study of Chlamydial Infection in Women 
Schillinger et al.32 conducted a trial of PDPT compared with patient referral in women with 
uncomplicated chlamydial infection from 1996 to 2000 in 6 metropolitan areas, including 
San Francisco, California; Seattle, Washington; New Orleans, Louisiana; Birmingham, 
Alabama; Indianapolis, Indiana; and urban southern California (Long Beach, Torrance and 
Los Angeles). Patients were diagnosed in family planning, teen health, primary care, and 
STD clinics, and emergency departments.  Initial chlamydial infections were diagnosed by 
various tests in routine use at the participating clinics, and follow-up infections were 
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determined by nucleic acid amplification tests (NAAT) (specifically, ligase chain reaction 
[LCR] or polymerase chain reaction [PCR]) testing of urine specimens.  A total of 1,787 
eligible subjects were randomly assigned either to partner management by PDPT with 
single doses of 1.0 g azithromycin (for up to 4 partners) or to patient referral.  In both 
groups the subjects were counseled to tell their partners about exposure and to encourage 
the partners to seek treatment.  Those in the PDPT arm were provided with packets for 
delivery to their partners that contained powdered azithromycin, instructions on drug 
reconstitution and administration, advice about possible adverse effects and to abstain from 
sexual intercourse until 7 days after treatment, and a fact sheet about chlamydial infection.  
Control subjects, but not those in the PDPT arm, were provided with a list of clinics where 
their partners could obtain cost-free care. 
Follow-up visits were scheduled 1 month and 4 months after enrollment.  At least 1 follow-
up visit was completed >3 weeks after treatment in 728 (82%) of 887 patients assigned to 
PDPT and 726 (81%) of 900 controls.32  The control and intervention groups were similar 
demographically and in several behavioral measures.  Women found to be infected at the 
first follow-up visit were not followed thereafter.  At the first follow-up visit, C. 
trachomatis was identified in 37 women (5.1%) in the PDPT group and 54 (7.4%) of those 
in the patient referral arm. Among women who were chlamydia-negative at the first 
follow-up and were followed again a median of 13 weeks after treatment, C. trachomatis 
was identified in 50 (11.1%) of 450 women in the PDPT arm and 54 (12.2%) of 443 
controls.  Thus, the cumulative prevalences of persistent or recurrent infection were 87 
(12.0%) of women in the PDPT arm and 108 (14.9%) of controls (OR 0.80, 95% CI 0.62-
1.05, P = 0.102). (The analysis assumed that women who tested negative at 1 month and 
were not followed further remained uninfected.)  This effect remained after adjusting for 
patient age and study center, and the risk of reinfection was not correlated with compliance 
with the intervention within each study arm.  Among women who reported a new sex 
partner after treatment and before follow-up, those the PDPT arm were more likely to be 
reinfected than women in the patient referral arm. 
Gonorrhea and Chlamydial Infection in Men and Women, King County, Washington 
From 1998 to 2003, Golden et al.33 contacted 7,723 patients with reported gonorrhea or 
chlamydial infection (among 26,656 reported cases).  After excluding 2,471 persons who 
declined study participation and 2,501 who believed all partners at risk had already been 
treated, the investigators randomized 2,751 subjects to EPT (N = 1,376) or standard partner 
management (N = 1,375).  Nineteen percent of enrolled subjects were diagnosed in public 
STD clinics, 23% in other public health clinics, 13% in community or family planning 
clinics, 12% in hospital emergency departments, and 33% by other clinicians in the private 
sector. Statistically significant differences between participants and those who declined 
participation were found in age (mean 23.2 and 25.2 years old, respectively, P<0.001), 
gender (74% and 64% female, P<0.001), diagnosis with gonorrhea without chlamydial 
infection (13% and 18%, P<0.001), diagnosis in emergency departments (10% and 6%, 
P<0.001), and diagnosis in family planning or community clinics (16% and 18%, P = 
0.009). 
For patients with gonorrhea, EPT consisted of cefixime 400 mg plus azithromycin 1.0 g; 
azithromycin alone was administered for chlamydial infection.  The medications were 
delivered in “partner packs” that contained drug and written materials with instructions on 
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drug administration, warnings about possible side effects and allergic reactions, fact sheets 
about gonorrhea and/or chlamydial infection, and a list of clinics where cost-free STD care 
was available. In the EPT arm, index patients enrolled in the STD clinic who were able and 
willing to contact their partners were given partner packs for up to 3 partners.  Participants 
randomized to EPT who were enrolled by telephone retrieved partner packs at pharmacies 
that had agreed to collaborate in the project.  When index patients were unable or unwilling 
to contact their partners, study personnel contacted the partners and arranged for the 
partners to retrieve partner packs from the cooperating pharmacies.  The standard arm was 
patient referral for subjects who were willing and able to contact their partners and provider 
referral by study personnel for others.  Index patients or study personnel advised the 
partners to attend the STD clinic or to visit their own health care providers for treatment, 
and were provided written materials as in the EPT arm, without the medication-specific 
information.  Index patients in both study arms were followed for interview and for urine 
NAAT testing for C. trachomatis and Neisseria gonorrhoeae by NAAT (LCR or 
transcription mediated amplification [TMA]). There were no significant differences 
between study arms in the distribution of gonorrhea or chlamydial infection, gender, age, 
race, ethnicity, type of health care facility where the diagnosis was made, symptoms, 
number of sex partners, or frequency of condom use in the 60 days before enrollment. 
The prevalences of persistent or recurrent infection at follow-up are summarized in Figure 
3. Follow-up 3-19 weeks after enrollment was 68% in each arm.  The protocol-defined 
primary outcome of persistent or recurrent infection with either N. gonorrhoeae or C. 
trachomatis was found in 92 (9.9%) of 929 patients in the EPT group and 121 (13.0%) of 
931 controls (OR 0.76, 95% CI 0.59-0.98, P = 0.04).  The reduction in persistent or 
recurrent infection was greater for gonorrhea (OR 0.32, 95% CI 0.13-0.77, P <0.01) than 
for chlamydial infection (OR 0.82, 95% CI 0.62-1.07, P = 0.17).  Table 3 summarizes the 
prevalence of infection at follow-up separately for men and women and for each infection.  
EPT remained independently associated with a lower prevalence of infection with either 
organism at follow-up (OR 0.7, 95% CI 0.6-1.0) after adjustment for gonorrhea versus 
chlamydial infection, index patient age, the clinical setting where the diagnosis was made, 
race/ethnicity, resumption of sex following treatment, and number of partners with whom 
index patients had unprotected sex since treatment (Table 4).  (Factors associated with the 
outcome on univariate analysis but which were believed to be in the causal pathway for the 
effects of EPT, such as the index cases’ belief that all partners at risk had been treated, were 
excluded from the final multivariate model.) 
Golden et al offered 4 hypotheses to explain the weaker association with chlamydial 
infection than gonorrhea at follow-up.33 Three of these (differences between patients with 
gonorrhea or chlamydial infection in successful delivery of therapy to partners; differences 
in resumption of sex with untreated partners; and differences in receipt of antibiotic therapy 
in addition to the initial treatment) were not supported by data from the index case 
interviews at follow-up. The fourth hypothesis was that chlamydial infections in women 
may persist following therapy more frequently than do gonococcal infections.  Among 
women with chlamydial infection, 289 (21.8%) of 1,328 who returned for follow-up denied 
sex with any partner since treatment, as did 38 (18.9%) of 201 women with gonorrhea who 
were followed. C. trachomatis was identified at follow-up in 22 (7.6%) of the 289 subjects 
who denied sexual exposure since treatment, whereas N. gonorrhoeae was found in 1 (3%) 
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of the 38 female gonorrhea patients who denied sex after treatment (Figure 4).  None of 87 
men who denied sex after treatment was infected with either organism. 
Urethritis in Men, New Orleans 
From December 2001 to March 2004, Kissinger et al.34 enrolled 977 male STD clinic 
patients with symptomatic urethritis into a 3-arm RCT of PDPT, patient referral, or booklet-
enhanced partner referral (BEPR), i.e. patient referral supplemented with a booklet that 
provided information about gonorrhea and chlamydial infection.  Patients were enrolled on 
the day of presentation, before the diagnosis was bacteriologically confirmed, and the EPT 
regimen for all patients was azithromycin 1.0 g plus either cefixime 400 mg or 
ciprofloxacin 500 mg.  Subsequent diagnostic testing documented gonorrhea alone at 
enrollment in 54.5% of subjects, chlamydial infection alone in 15.0%, and both infections 
in 5.9%; neither infection was found in the remaining 25%.  Seven hundred seventy men 
(79%) returned for follow-up 2-8 weeks after enrollment, but testing for N. gonorrhoeae 
and C. trachomatis was available for only 289 men (37.5%), attributed by the authors to 
multiple factors, including patients’ fears that testing for illicit drugs would be conducted 
on urine. The subjects tested were similar to those not tested in all demographic and 
behavioral characteristics measured at baseline and in the proportion who had sex with a 
new partner since treatment (14% of those who permitted testing and 13% of those who did 
not). Follow-up tests were permitted by 43% of men randomized to BEPR compared with 
33% of those managed with EPT or standard partner referral (P <0.05). Testing at follow-up 
was accomplished by the strand displacement NAAT of urine in 242 subjects, and in 47 
men by non-amplified DNA probe test on urethral swab specimens. 
The results are summarized in Table 2.  For subjects with either chlamydial infection, 
gonorrhea or both, infection was present at follow-up in 35 (43%) of 82 men in the patient 
referral arm (referent), 20 (23%) of 87 managed with PDPT (adjusted OR 0.38, 95% CI 
0.19-0.74), and 16 (14%) of 112 in the BEPR arm (adjusted OR 0.22, 95% CI 0.11-0.44).  
Compared with patient referral, the reduction in infection prevalence at follow-up in the 
PDPT arm was similar for gonorrhea (OR 0.34, 95% CI 0.13-0.86) and chlamydial 
infection (OR 0.46, 95% CI 0.13-0.87). Using an intention-to-treat mode, reinfection rates 
for subjects in both the PDPT and BEPR conditions remained significantly lower than in 
the control condition. In an analytic model in which all untested men were assumed to be 
uninfected at follow-up, the prevalences of persistent infection were 5.8% for PDPT, 4.6% 
for BEPR, and 12.3% for subjects managed with standard patient referral (P<0.01).34 
Trichomoniasis in Women, New Orleans 
From 2001 to 2004, Kissinger et al.35 conducted a trial of PDPT in 463 women with vaginal 
trichomoniasis in an STD clinic.  PDPT with single doses of metronidazole 2.0 g was 
compared with patient referral and BEPR, as described above.  Infection at baseline and 
follow-up was diagnosed by culture of Trichomonas vaginalis. The prevalences of 
infection at follow-up are summarized in Table 2.  Among 376 women followed 3-7 weeks 
after enrollment, persistent or recurrent trichomoniasis was documented in 8 (6%) of 126 
women in the patient referral group (referent), 12 (9%) of 128 patients randomized to 
PDPT, and 11 (9%) of 122 in the BEPR arm (P = 0.6).  The results were not substantially 
different when controlled for several demographic and behavioral variables.  The 
investigators hypothesized that the absence of measurable differences in treatment 
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outcomes may reflect a higher-than-expected treatment failure with single-dose 
metronidazole in index patients, partners, or both.  In addition, the 73% compliance rate for 
the patient referral (control) arm was substantially higher than expected, requiring a larger 
than anticipated sample size to document possible differences. 
Randomized Controlled Trials: Behavioral Outcomes 
The 4 RCTs32-35 included self-reported behavioral outcomes derived from interviewing 
subjects who returned for follow-up, and many measures were similar across these studies 
in both design and procedure.  Because of these similarities, and because desirable 
behaviors of patients and partners are common to all three STDs studied (gonorrhea, 
chlamydial infection, trichomoniasis), the results in three domains—partner notification 
behaviors, patients’ perceptions that their partners were treated, and sexual behaviors 
following treatment—were combined. 
Partner Notification 
In 3 RCTs,33-35 index patients were directly asked at follow-up whether they had notified 
their partners.  In the other trial, Schillinger et al.32 asked trial participants whether they 
complied with the intervention, which required women in both arms to notify their partners 
that they had been exposed and recommend they be evaluated and treated, and for women 
in the PDPT arm to deliver medication to their partners.  The results from all 4 trials are 
summarized in Table 5. For PDPT, 505 (85%) of 591 women responded affirmatively, 
compared with 431 (75%) of 576 controls (P<0.01).  In the New Orleans urethritis trial,34 
participants were directly asked whether they notified their partners:  500 (71%) of 705 men 
randomized to PDPT reported that they did so, compared with 280 (48%) of 579 in the 
patient referral arm (P<0.001) and 375 (53%) of 707 men managed with booklet-enhanced 
partner referral (BEPR) (P<0.001). 
In the King County study33 and the New Orleans trichomoniasis trial,35 the rates of reported 
partner notification were virtually identical for EPT and standard partner management:  
77% of 1,335 EPT patients versus 78% of 1,403 controls in King County; and 90% of 176 
for EPT versus 88% of 173 patients in the patient referral arm in New Orleans (Table 5).  
The rate was 84% of 172 New Orleans women in the BEPR group.  None of the observed 
differences was statistically significant.  The especially high rates of partner notification 
observed in New Orleans (84 – 90%) may have resulted from enhanced counseling in all 
trial conditions; all participants received expanded instructions and education about the 
importance of notification that were not routine in the authors’ clinic.  
Partner Treatment 
The participants in all 4 RCTs were asked if they believed their partners were treated, and 
in two trials they were asked whether they observed their partners take medication (Table 
6). Among women with a single partner at enrollment in the 6-city trial, 518 (86%) of 602 
subjects in the PDPT arm thought it “very likely” that their partners took the medication, 
compared with 392 (57%) of 681 women in the patient referral arm who stated it was “very 
likely” that the partners had been treated (P<0.001).  In King County,33 816 (64%) of 1,268 
participants in the EPT group and 732 (52%) of 1,354 persons randomized to standard 
management reported that their partners “very likely” were treated (P<0.001); and 519 
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(61%) of 850 EPT patients versus 435 (49%) of 888 controls reported that all partners at 
risk had been treated (P<0.001). 
In the New Orleans urethritis trial34 the subjects managed with PDPT reported compliance 
with the intervention for 70% of their partners, compared with 48% of the partners of men 
in the patient referral arm (P<0.001) and 58% of those in the BEPR arm (P<0.01).  The 
index cases in the PDPT arm reported that 56% of their partners said they took medication, 
compared with 34% for patient referral and (P<0.001) and 44% for BEPR (P<0.01).34 
Among women with trichomoniasis studied in New Orleans,35 the patients randomized to 
PDPT observed 63% of their partners take the drug, compared with 18% for patient referral 
(P<0.001) and 20% in the BEPR arm (P<0.001). However, in the same trial women 
randomized to PDPT were no more likely than those in the standard management group to 
report that their partners said they took medication (77% vs. 70%, P = NS).  Women in the 
BEPR condition reported that only 58% of their partners said they took their medications 
(P<0.01 compared with PDPT).35 
Sexual Behavior Following Treatment 
Schillinger et al.32 asked their study subjects whether they had acquired new sex partners 
between treatment and follow-up; 167 (23%) of 728 women in the PDPT arm had done so, 
compared with 201 (28%) of 726 randomized to patient referral (P<0.05) (Table 7).  In the 
King County study,33 51 (5.8%) of 886 participants randomized to EPT had sex following 
treatment with >1 partner who had neither been treated nor tested and found to be negative 
for STDs, compared with 110 (12.2%) of 902 controls (OR 0.5, 95% CI 0.3-0.6, P<0.01) 
(Table 7). 
Although the two New Orleans trials studied the same interventions, significantly different 
sexual behavior outcomes were observed for men with urethritis and women with 
trichomoniasis (Table 7).34,35 Men managed with PDPT reported unprotected sex before 
partner treatment with 28% of their partners, compared with 37% of partners of men in the 
patient referral arm (P<0.05), and 35% of partners of men in the BEPR arm (P = NS).34 
Among women with trichomoniasis, the comparable outcomes were 8% for PDPT, versus 
5% for the patient referral arm (P = NS) and 6% for BEPR (P = NS).35  After treatment, 
29% of men managed with PDPT reported unprotected sex during the follow-up period 
with their partners, compared with 34% of men in the patient referral arm and 37% of men 
in the BEPR arm (P = NS).  By contrast, 26% of women with trichomoniasis randomized to 
PDPT reported unprotected sex during follow-up with their partners, versus 13% of women 
managed with patient referral (P<0.01) and 16% of women managed with BEPR (P<0.05). 
Randomized Controlled Trials: Cost Effectiveness 
A retrospective cost effectiveness analysis36 was conducted based on the results of the 6-
city trial.32  Providing PDPT for all partners, which was the most effective method of 
treating the male partners of women enrolled in the study, was the model that resulted in the 
fewest number of cases of PID in the index women.  When the costs of averted sequelae 
were considered, PDPT was cost-saving compared either to standard patient referral, or to a 
modeled strategy of selective PDPT in which medication was assumed to be provided for 
delivery to only those partners women believed unlikely to seek care.  When considering 
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only program costs, i.e. excluding the costs of sequelae, PDPT was slightly more expensive 
than either patient referral or the selective PDPT strategy, because an individual clinic or 
program typically does not realize the cost savings that result from preventing sequelae.  
The program cost of PDPT per index patient was higher per index patient ($32) than the 
alternative of standard patient referral ($28) or the modeled option of selective EPT ($28).  
However, because treatment rates were higher, EPT was less costly per infected partner 
treated ($82 versus $137 and $130, respectively).  EPT was cost-saving compared to the 
alternatives when costs of averted sequelae were included in the analysis.36 
Cost effectiveness analyses37 were incorporated prospectively into the King County and 
New Orleans trials of EPT for chlamydial infection and gonorrhea.32,33 Literature estimates 
were used for the costs of sequelae, the proportions of other partners likely to be infected, 
and the costs of unobserved patient visits to health care providers.  Cost effectiveness was 
analyzed from programmatic and health care systems perspectives.  In the King County 
trial.33  Personnel costs were derived from prospective records of the time spent by study 
personnel in contacting providers, patients and pharmacies, and for related administrative 
work; these variables were designed to mimic those anticipated in implementation of 
partner management in a typical health department.  EPT was found to be cost-saving 
compared to standard partner management as practiced in the trial (patient referral or 
provider referral, depending on the subjects’ willingness and ability to personally contact 
their partners), and remained cost-saving whether or not the costs of sequelae averted were 
included in the analysis. Because public health personnel or resources are not involved in 
partner management for most patients with gonorrhea or chlamydial infection treated in 
U.S. health departments,12 the analysis was repeated without these expenditures.  The 
programmatic cost of EPT was $200 more per additional infected partner treated than for 
standard patient referral or provider referral.  When the costs of sequelae averted were 
included in the analysis, EPT was cost-saving compared to the low-cost referral model that 
had been adjusted for public health expenditures for male index patients, but not for female 
index patients. In any particular program, the latter figure would be highly sensitive to the 
proportion of patients managed by patient referral, provider referral, conditional referral, or 
other mechanisms.37 
In the New Orleans urethritis trial,34  the program cost of EPT per index patient ($60) was 
found to be lower than the equivalent costs for standard patient referral ($81) or booklet-
enhanced partner referral (BEPR) ($79).37  The cost per infected partner treated was $86 for 
EPT, compared with $193 for standard referral and $176 for BEPR.  The difference was 
primarily the result of reduced numbers of health care visits by partners managed by EPT.  
EPT remained substantially less costly than the control interventions after adjustment for 





Numerous practical issues will influence implementation of EPT and its priority compared 
with traditional partner management strategies.  Except where indicated, this discussion 
addresses EPT for chlamydial infection and gonorrhea. 
Special Populations 
The 4 available RCTs and other evaluation studies are largely limited to heterosexual adult 
men and women, whereas EPT may be used for other populations diagnosed with STD, 
such as men who have sex with men (MSM), pregnant women, and adolescents.  No data 
are known to exist on EPT for gonorrhea or chlamydial infection among MSM.  The rates 
of syphilis, gonorrhea and probably of chlamydial infection in MSM are substantially 
higher than in most heterosexual populations and have been rising rapidly in all 
industrialized countries.38  All partner management strategies have variable success in this 
population because of high rates of partner change and anonymous partnerships, which 
would challenge the efficacy of EPT. Further, it is likely that high prevalences of co-
morbidities, including HIV infection, other STDs, substance use, and psychological 
impairment favor traditional partner management over EPT in MSM.   
Pregnant women were not separately analyzed in the available trials of EPT.  Because of 
potential adverse effects of gonococcal or chlamydial infection on the course of pregnancy 
and neonatal health, preventing reinfection may be a higher priority than in nonpregnant 
women.  On the other hand, most pregnant women have ready access to health care and 
many are highly motivated to protect the health of the fetus, factors that are likely to 
enhance the success of traditional partner management and might reduce the role of EPT.    
Improved partner management is a high priority among heterosexual adolescents,39,40 
among whom the rates of gonorrhea and chlamydial infection in females outstrip those of 
all other age groups.41  Recent data on partner notification in teens assessed dispositional 
correlates of success, such as self-efficacy and relationship quality.24  No studies have 
explicitly addressed EPT in predominantly adolescent populations.  Slightly over half the 
patients in the 6-city RCT of women with chlamydial infection were aged 14-19 years, and 
the results were not materially different than in the study population as a whole, with 
prevalences of infection at follow-up of 13% of in the EPT arm and 17% of controls (P = 
0.09).32 However, few subjects were <16 years old, and useful data are lacking on the 
efficacy of EPT in young teens. 
Other Sexually Transmitted Diseases 
In many settings, EPT may be a consideration in partner management for STDs other than 
those studied to date. Partners of patients with NGU, MPC, or PID often are treated before 
the results of diagnostic tests are available, and some providers likely will use EPT without 
knowledge of microbiologic etiology.  The utility of partner treatment in reducing 
morbidity in partners or preventing reinfection has not been established for nonchlamydial 
NGU or MPC. Uncertainty about how to manage partners is an important reason clinicians 
are encouraged to test all patients with NGU, MPC, or PID for N. gonorrhoeae and C. 
18 

trachomatis.  Syphilis requires injection therapy with benzathine penicillin G, precluding 
PDPT and most other EPT strategies.  Azithromycin may have promise as a single-dose or 
two-dose oral option for treatment of persons with infectious syphilis and their partners,42,43 
and was transiently used by some health departments as PDPT for MSM with syphilis.44 
However, high and rising rates of azithromycin-resistant strains of Treponema pallidum and 
substantial rates of treatment failure following azithromycin therapy preclude EPT with 
azithromycin unless and until expanded research establishes the safety and efficacy of such 
treatment.45,46  It seems likely that some providers now use EPT in the management of some 
patients with scabies, pediculosis pubis, and perhaps genital herpes or other STDs, but no 
data are known to exist on these practices.  
STD Co-morbidity in Partners 
If partners receiving EPT do not seek evaluation, EPT may incur missed opportunities for 
diagnosis and therapy of STDs that would be detected by personal evaluation of the 
partners.  Stekler et al.47 reviewed the medical records of 4 urban STD clinics (Baltimore, 
Birmingham, Denver and Seattle) to determine the prevalence of STDs in persons named as 
partners of persons who gave their reason for clinic attendance as sexual contact with 
persons who had gonorrhea, chlamydial infection, NGU or trichomoniasis (Table 8). The 
STD contact histories were self-reported, without corroboration by record review or by 
other methods.  Among 8,623 patients, 28 (0.3%) had infectious syphilis; 24 of these were 
in a single clinic (Baltimore), where the 1.1% prevalence of syphilis was substantially 
higher than in the other clinics. Infectious syphilis was present in 8 (1.7%) of 473 MSM. 
Among female partners of men with gonorrhea, chlamydial infection or NGU, acute PID 
and trichomoniasis were diagnosed in 3.8% in 4.9%, respectively.  Previously undiagnosed 
HIV infection was present in 19 (0.4%) of 4,716 heterosexual men and women and 13 (6%) 
of 207 MSM. Among 785 male partners of women with trichomoniasis, 81 men (10.3%) 
had gonorrhea or chlamydial infection; in Birmingham the prevalence was 15%. 
STD contact was self-reported, and the clinics’ databases do not systematically record 
patients’ histories of contact with multiple STDs, factors that limit the interpretation of this 
study. Another important limitation is that patients who attend STD clinics as partners of 
persons diagnosed with STD probably are not representative of partners who do not seek 
care, or partners who seek care in venues other than STD clinics. 
Effects on Bacterial Ecology and Antimicrobial Resistance 
The recipients of EPT have indications for antimicrobial therapy.  Nevertheless, a 
substantial increase in relatively unsupervised antibiotic usage might raise concerns about 
the effects on bacterial ecology and antimicrobial resistance.  However, the incremental 
effect of EPT on overall antibiotic use likely would be small.  For example, about 55 
million prescriptions for azithromycin and other macrolide antibiotics are written in the US 
annually.48  Even if azithromycin could be successfully administered through EPT and 
other means to one sex partner for each of 3 million estimated annual cases of incident 
chlamydial infection, the increment in macrolide prescriptions would approximate 5%; the 
actual increment in macrolide use would be much smaller.  Similar considerations apply to 
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single-dose treatment with fluoroquinolones and cephalosporins.  Use of doxycycline 
probably carries a greater risk of adverse ecological outcomes than the other options, 
because unused medication from multiple-dose regimens undoubtedly increases the 
potential for unsupervised later use. 
Adverse Effects of Drugs 
Drug toxicity and allergic reactions in partners treated without direct medical supervision 
are potential problems for all drugs likely to be used for EPT in managing patients with 
chlamydial infection, gonorrhea or trichomoniasis.  Less serious but more frequent adverse 
outcomes consist primarily of transient gastrointestinal intolerance.  Delivery of dual 
therapy active against both gonorrhea and chlamydial infection increases the risk of adverse 
reactions and drug intolerance. Doxycycline and the fluoroquinolones carry theoretical 
risks for adverse effects in pregnant women or the fetus, but the actual frequencies of fetal 
and pregnancy-related morbidity are low. Metronidazole carries risks of gastrointestinal 
intolerance, allergic reactions, and disulfiram-like reactions in association with alcohol 
ingestion. The potential for reducing the frequency of adverse effects represents a 
particular advantage of EPT strategies that depend on delivery of drug by pharmacies, 
whether by written prescription or other means.49 
Missed Opportunities for Prevention Counseling 
Compared with personal evaluation in a health care setting, treatment by EPT represents a 
missed opportunity for professional counseling of patients’ sex partners, and there is broad 
consensus that partners who are willing and able to attend for personal care should be 
encouraged to do so. However, few data are available to judge the prevention efficacy of 
such counseling, especially when provided by typical primary care providers, or to 
document that its prevention benefit outweighs that which might accrue through 
educational literature that might accompany EPT or counseling by a pharmacist; or the 
relative efficacies, on a population level, of such counseling compared with overall 
enhanced partner treatment.  McCree et al. encouraged pharmacists to embrace counseling 
and educational responsibilities related to EPT, as an initial interface between sex partners 
and the health care system.49  One facet of pharmacy-based counseling would be to 
encourage recipients of EPT to seek medical evaluation.  An expanded role of pharmacies 
in STD partner management is consistent with increasing involvement by pharmacists in 
preventive medicine through blood pressure monitoring, immunization, provision of 
emergency contraception, and other initiatives. 
Legal Status of EPT 
Providing a prescriptive drug to a patient with whom the clinician lacks an established 
provider-patient relationship is not legal in some states, and elsewhere may be incorrectly 
perceived by providers as illegal. Golden et al. surveyed the directors of medical practice 
boards and pharmacy boards in 2003 in order to assess the legal status of EPT in the 50 
states.50  Usable responses were received from either or both sources from 47 states.  In 4 
states (Washington, California, Colorado, Tennessee), both respondents stated that EPT is 
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legal. The practice was classified by both respondents as illegal in 30 states, but many of 
the respondents expressed uncertainty and stated that the issue had never been directly 
addressed in their states.  The medical and pharmacy board representatives in 3 states 
(Arizona, Oregon and North Carolina) gave conflicting responses.  In 42 states where EPT 
was not known to be legal, most respondents expressed uncertainty as to whether 
enforcement action would be taken against providers who pursued the practice.50 
Medicolegal Concerns 
The risk of litigation in the event of adverse outcomes may be elevated (or perceived by 
practitioners to be elevated) when a practice has uncertain legal status or is outside formally 
accepted community practice standards.  Guidance from authoritative bodies may help 
determine community standards of care and thereby influence the assessment of 
medicolegal impediments to EPT.  
Funding 
When clinicians simply integrate EPT into their existing practices, the primary increased 
cost may be that of drug therapy per se, which often will be absorbed by index cases or 
their partners.  The importance of this obstacle will vary widely between patients and in 
various settings. Increasingly comprehensive programs by public health departments, 
health maintenance organizations, or other agencies will incur additional costs, including 
expenses incurred in counseling index patients, purchasing drugs, development of 
educational literature, packaging drugs and counseling aids, administrative expenses 
incurred by arrangements with pharmacies, personnel time when medications are delivered 
to patients by public health workers, and others.  The cost effectiveness studies undertaken 
in connection with 3 RCTs of EPT had promising outcomes, suggesting that 
institutionalized EPT in health department settings likely is cost-saving and probably is a 
cost effective partner management strategy.36,37  The expenses of EPT may be modest in 
relation to the total costs incurred in diagnosis and management of patients with treatable 
STDs, and in relation to the potential to prevent complications and curtail the spread of 
infection.37  Nevertheless, even small incremental costs may cause difficulties for under-
funded public health departments, especially those that now expend few resources on 
partner management for STDs other than syphilis and HIV infection. 
The same cost effectiveness considerations are relevant to patients treated in 
institutionalized settings other than health departments, such as health maintenance 
organizations and managed care plans.  Partner management strategies that reduce risk of 
persistent or recurrent gonorrhea and chlamydial infection may influence some such 
agencies and health insurers to finance EPT for their enrollees’ sex partners.  Others 
undoubtedly will demur for logistical and administrative reasons or because of medicolegal 
considerations, in particular perceived liability for adverse effects in non-enrolled patients.  





Pharmacy laws or policies may require that identifying information be recorded for persons 
receiving prescription drugs. At the same time, stipulations of the Health Information 
Portability and Accountability Act (HIPAA), as well as historic concerns for patient 
confidentiality, may preclude documenting a partner’s identity in an index patient’s medical 
record. To surmount this obstacle, some programs have established pharmacy records that 
are separate from patient records.  Recent legislation in Tennessee permits EPT for 
unnamed partners, presumably facilitating recording of all necessary information in index 
patients’ medical or pharmacy records.  In many jurisdictions providers and health care 
agencies are likely to require guidance on implementation of EPT while guarding the 
privacy of both index patients and partners and to comply with HIPAA.   
Drug Delivery and Packaging 
PDPT, either of medications per se or of prescriptions, undoubtedly will be the usual 
mechanism for EPT, especially in the private sector.  Acceptance of PDPT for chlamydial 
infection in San Francisco initially was low,51 but qualitative research among recipients of 
PDPT with azithromycin for syphilis in the same setting revealed that professional-
appearing (and therefore more costly) packaging enhanced patient acceptance.44  However, 
some patients will be unwilling or unable to assist in contacting or treating one or more 
partners, and optimal use of EPT may depend on partners retrieving drug at pharmacies, 
health department clinics, or other facilities, or delivery of medications DIS or other 
outreach workers. There is broad consensus that EPT should be accompanied by written 
materials that include descriptions of the STD of concern, symptoms of infection, advice 
that personal evaluation is preferable to self-treatment, sources of STD-related health care, 
and information about potential adverse effects and allergic reactions.  In some settings, 
packaging and delivery of drugs and accompanying materials may carry significant 
administrative and financial costs.   
Providers’ and Health Agencies’ Attitudes and Beliefs 
It is likely that multilayered attitudinal differences have long existed between most public 
health agencies’ recommendations, some providers’ practices, and providers’ beliefs about 
the appropriateness or utility of EPT. Historically, public health experts and agencies have 
overtly or tacitly condemned EPT, yet some providers employed it frequently and at least 
half did so sporadically for chlamydial infection or gonorrhea.25-28  These attitudes and 
beliefs undoubtedly will influence the acceptance and implementation of EPT.  There are 
other precedents for EPT-like uses of anti-infective drugs for prevention of communicable 
diseases, as when antibiotics are distributed to persons exposed to invasive meningococcal 
disease; when entire families are treated for pediculosis or pinworm infestation diagnosed 
in one member of the household; and when patients and employees of extended health care 
facilities are treated after diagnosis of a single case of scabies.  Nevertheless, some 
providers may not view these practices as precedents for EPT for STDs.  The California 
experience suggests that many providers who employ EPT for gonorrhea or chlamydial 
infection do so despite believing it to be suboptimal health care.27  Endorsement of EPT by 
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professional societies and organizations may be anticipated in the future, perhaps 
facilitating provider acceptance. 
Administrative Barriers and Organization of EPT 
Although EPT is presently in use by some providers at little apparent administrative cost, 
substantial barriers may exist at the institutional level.  To reach large numbers of persons 
diagnosed with gonorrhea or chlamydial infection, the King County trial of EPT33 depended 
on substantial cooperation and coordination between public health and the private sector, 
involving the health department, numerous health care providers and clinics, the local 
medical society, and pharmacies.23  This collaboration itself has been cited as a useful 
outcome of the study.52  A demonstration project designed to implement a similar system 
statewide, and to assess the impact of routine use of EPT on gonorrhea on the incidence and 
prevalence of infection at a population level, will soon be underway in the state of 
Washington (Golden MR, personal communication). 
Provider Education 
Few public health agencies currently employ EPT, and there is great variability in the 
frequency of use by private health care providers.17,25-27  It is likely that most providers have 
not systematically considered the advantages, disadvantages, costs, and barriers associated 
with various partner management strategies for particular STDs and in various populations 
at risk. These facts imply a need for a concerted and focused effort to educate providers on 
all partner management strategies. 
Interaction with Other Partner Management Strategies 
The resources available and index patient willingness to bring or refer his or her partners 
for personal evaluation and the availability and expected effectiveness of provider referral 
will influence implementation of EPT.  Some patients will be willing and able to refer their 
partners for traditional care, with confidence the partners will comply, and in other settings 
effective provider referral may be available.  EPT may have a lesser role in partner 
management in such settings.  Most health departments have insufficient resources to 
attempt to provide partner services for persons with gonorrhea, but 6 jurisdictions (each 
with <2,500 annual cases of gonorrhea) of 60 surveyed reported that they attempted to 
initiate partner services for >80% of persons with gonorrhea.12  Data are generally not 
available from those jurisdictions to judge overall effectiveness of partner management, but 
EPT may have a lesser role for gonorrhea management in those settings than others.  
Similar data are not available for chlamydial infection.  
Retesting for Chlamydial Infection and Gonorrhea  
Retesting of women, also called rescreening, is emerging as an important strategy for 
control of chlamydial infection.53-55  Some providers might believe that enhanced assurance 
that partners received treatment reduces the need for retesting, but the results of 3 RCTs of 
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EPT reviewed in this report reconfirm the importance of retesting women following 
treatment of chlamydial infection, regardless of the partner management strategy employed, 
and highlight its probable importance for men with chlamydial infection and both men and 




Summary and Interpretation of the Randomized Controlled Trials 
Persistent and Recurrent Infection Following EPT 
In 4 RCTs, the frequency of persistent and recurrent infection following EPT compared to 
standard partner management was assessed among persons with gonorrhea, chlamydial 
infection, or trichomoniasis.  The effects were largely consistent across the trials, but varied 
according to disease and gender.  In two RCTs that evaluated men with gonorrhea or 
chlamydial infection to assess treatment of their female partners,33,34 EPT was associated 
with reduced rates of reinfection compared with patient referral and/or provider referral.  
However, the combined sample size of males available for biomedical follow-up is modest.  
In the King County trial,33 this information is available for 157 men with gonorrhea and 267 
men with chlamydial infection.  In New Orleans,34 persistent or recurrent infection was 
measured in 289 men with either infection.   
In women, the association of EPT with a reduced prevalence of infection at follow-up was 
weaker for chlamydial infection32,33 than gonorrhea.33  In the King County trial, 7.6% of 
female index cases with chlamydial infection who were treated with azithromycin and 
denied all sexual exposure after treatment nevertheless were infected at follow-up.33  By 
contrast, among patients who denied sex following treatment, only one woman had 
gonorrhea at follow-up and no man had either infection.  Analysis of the determinants of 
persistent or recurrent chlamydial infection in 5 of the centers (and most of the same 
clinics) where the 6-city trial32 was subsequently conducted also suggested a higher than 
expected rate of persistent infection in women who denied sexual reexposure.53  Thus, the 
apparent efficacy of both EPT and the control strategies in preventing reinfection with C. 
trachomatis may have been reduced by a higher-than-expected rate of persistent infection at 
follow-up. Highly sensitive NAATs were used to detect chlamydial infection in the EPT 
trials32-35 and the 5-city cohort study of reinfection that preceded it,53 whereas culture was 
employed in most published studies designed to determine the efficacy of azithromycin 
against C. trachomatis.56  In addition, the therapeutic trials typically followed patients at 3-
6 weeks,56 compared with 6-20 weeks follow-up in the EPT-related studies.32-35,53  Other 
evidence also suggests that persistent C. trachomatis following treatment with azithromycin 
may be more common than previously believed.57 
The single available RCT of EPT for trichomoniasis in women did not demonstrate a 
significant difference in the prevalence of persistent or recurrent infection compared with 
either standard or booklet-enhanced patient referral, and mixed results were observed for 
desirable behavioral outcomes.35  The trial is limited in its generalizability because the 
population studied, almost exclusively minority patients of low socioeconomic status in a 
southern, inner city STD clinic, is poorly representative of many women with 
trichomoniasis.  Further, the control subjects displayed an unexpectedly high success rate of 
73% in referring their partners for treatment, perhaps challenging the ability of the study to 
document differences in outcomes between the study arms.  Finally, higher than expected 
rates of persistent or recurrent infection might have contributed to the outcome.  The 
recommended 2.0 g metronidazole regimen used in the trial cures 90-95% of cases,58,59 
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compared with >96% cure rates for the recommended gonorrhea and chlamydial regimens.  
No studies have assessed the efficacy of metronidazole using maximally sensitive tests of 
cure such as PCR for T. vaginalis,60 raising the possibility that the actual cure rate is <90% 
in men, women, or both.  Tinidazole may be more effective than metronidazole.59,61 
Behavioral Outcomes Associated with EPT 
All 4 RCTs reviewed incorporated assessment of behavioral outcomes in addition to the 
primary outcome of persistent or recurrent infection.32-35  Across the 4 trials, according to 
interviews of the index cases at follow-up, EPT resulted in higher or equivalent frequencies 
of partner notification and partner treatment.  In 3 of the trials,32-34 EPT was associated with 
lower frequencies of behaviors that would risk reinfection, including sexual re-exposure to 
untreated partners and unprotected sex with new partners.  In the trichomoniasis RCT, 
however, EPT was associated with a greater likelihood of unprotected sex compared with 
standard management.35  The generally favorable outcomes associated with EPT were 
based on self-report by subjects who might have overtly or unwittingly provided desirable 
responses, but there is no particular reason to believe that this potential bias was 
systematically associated with EPT compared with the control strategies.  Some of the 
behavioral outcomes, such as patients’ reports that they observed their partners ingest the 
medication and reduced frequency of post-therapeutic sex with untreated partners, 
undoubtedly are involved in the causal pathway for reduced prevalence of infection at 
follow-up. These findings give promise that behavioral outcomes may serve as surrogate 
markers for partner treatment success in less costly future studies that do not rely on 
prolonged follow-up to measure persistent or recurrent infection.   
Generalizability 
With rare exceptions, all RCTs raise questions of generalizability:  to what extent are the 
patient populations, interventions and outcomes pertinent to settings other than those 
represented in the trials?  The geographic distribution of the patients studied by Schillinger 
et al is an important strength of the 6-city trial, especially since PDPT was associated with 
similarly reduced rates of recurrent or persistent infection in 5 of the 6 study centers and 
across most subgroups analyzed.32  Data are not available on the proportion of potentially 
eligible subjects who were enrolled, how those persons compared with those not enrolled, 
and how the study population compares with other women infected with C. trachomatis. 
Golden et al.33 enrolled subjects diagnosed at a broad and well-documented range of 
clinical settings, with predominant representation from private practices and other non-
public clinics, and carefully characterized the study population, demonstrating substantial 
comparability to subjects who declined participation or were ineligible.  However, the trial 
was undertaken in a single metropolitan area that may not be representative of many 
jurisdictions where EPT might be employed.  For example, although racial and ethnic 
minorities were well represented in relation to the population of King County, the numbers 
and population proportions of minorities were small in comparison to those in many 
geographic areas. 
The design of both trials necessarily excluded subjects whose partners already had received 
treatment, i.e. patients in whom partner management (probably almost exclusively through 
patient referral) already was successful.  This is a particular issue for the King County trial, 
in which about half the potential subjects were excluded because the index cases believed 
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all partners at risk had been treated.  Thus, the study population probably was biased toward 
a subset of patients less likely than others to facilitate partner treatment, which might have 
reduced the apparent efficacy of both EPT and the control strategies.  It is likely that fewer 
patients enrolled in the 6-city trial32 had an opportunity to inform and arrange for treatment 
of their partners before enrollment, but the available data do not permit definitive 
assessment of this possibility.   
The New Orleans trials of EPT for urethritis in men34 and trichomoniasis in women35 
enrolled most patients at the time of diagnosis, before any effort had been made to assure 
referral and treatment of the subjects’ partners.  In this respect, the studies may more 
accurately reflect the implementation of EPT in settings where index case treatment and 
partner management are undertaken simultaneously, such as public STD clinics.  However, 
both New Orleans patient populations were composed almost entirely of African Americans 
attending an inner city STD clinic.  These patients may be more socioeconomically 
disadvantaged than many patients who may be offered EPT, especially in the private sector.  
The failure of many male subjects in New Orleans to provide urine specimens at follow-up, 
ostensibly because of fears that the specimens would be tested for illicit drugs, may have 
introduced undetected biases in the analysis of persistent or recurrent infection, and further 
may suggest particularly high rates of substance use that might challenge the 
generalizability of the findings. 
The 4 RCTs also had limited power to draw conclusions about efficacy for some 
combinations of disease, gender, and patient characteristics.  The available data do not 
permit definitive evaluation of disease-specific or gender-specific EPT outcomes in relation 
to potentially important confounders, such as age, socioeconomic status, education, clinical 
setting, and a variety of sexual behaviors. On the other hand, the consistency of both 
biological and behavioral outcomes for chlamydial infection and gonorrhea across 3 trials, 
despite substantial differences in population and study design, provides a measure of 
assurance that the results are robust and broadly applicable.  
Implementation Issues 
Of the numerous issues pertinent to systematic implementation of EPT as a partner 
management strategy, the potential for missed morbidity in partners, the legal status of 
EPT, and concerns about adverse effects of antibiotics probably are the dominant potential 
obstacles in most settings. 
Missed Morbidity 
There is particular concern that EPT in male index cases might foster underdiagnosis and 
undertreatment of complicated infections in their female partners, especially if women with 
overt or incipient PID forego medical evaluation.  Stekler et al.47 found that PID was 
diagnosed in almost 4% of women who gave their reason for attending STD clinics as 
exposure to men with STD, including but not limited to men with gonorrhea or chlamydial 
infection. The clinics in the study use clinical criteria for PID similar to those recommended 
by CDC for presumptive treatment, which are designed to maximize sensitivity and are 
relatively nonspecific.54  Therefore, the analysis might have overestimated the prevalence 
of symptomatic PID.  However, it is not known whether a higher or lower proportion of 
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women who attend STD clinics as contacts of infected men may have complications 
compared with women who have not yet sought clinical services.  Thus, special caution is 
warranted in use of EPT in men for delivery to their female partners.  On the other hand, the 
potential for missed PID is partly balanced (and may be exceeded) by an overall reduction 
in PID and its complications that might accrue from improved overall partner management.  
Similar but less urgent considerations apply to symptomatic male recipients of EPT, who 
should be encouraged to seek care in addition to (or instead of) accepting treatment. 
High prevalences of STD co-morbidity also can be expected in women with trichomoniasis 
and their partners,47,62 contributing to caution in use of EPT for trichomoniasis.  The reverse 
observation, a high likelihood of undiagnosed trichomoniasis in the partners of persons with 
gonorrhea or chlamydial infection,62 is less relevant to the use of EPT or other partner 
management strategies.  Sensitive diagnostic tests for T. vaginalis, such as PCR, are not yet 
widely available, and most cases of trichomoniasis in partners (and many cases in index 
patients with gonorrhea or chlamydial infection) will not be diagnosed regardless of the 
partner management strategy employed.  Stekler et al also found a 6% prevalence of 
undiagnosed HIV infection in MSM who gave STD exposure as their reason for visiting 
STD clinics,47 a significant issue in considering use of EPT in this population.  Finally, no 
data are available on the prevalence of non-STD morbidities in partners, such as substance 
abuse and mental health problems, although it is not clear that other partner management 
strategies are any more effective in detecting or preventing them. 
Legal Issues 
The legal status of EPT, whether real or perceived, will affect implementation.  Some 
clinicians apparently use EPT without obvious inhibition based on legal status,25 but most 
public health departments and many health care institutions, such as health maintenance 
organizations and managed care plans, will be constrained from formal institution of EPT 
until the legal status of EPT has been addressed in their jurisdictions.  Health officers in 
most or all states possess statutory powers to protect and maintain the public’s health, and 
in some states these powers may override laws or policies that apparently conflict with 
EPT. In others, administrative or judicial rulings may nullify apparent legal barriers, as 
occurred in the state of Washington (Klopfenstein L, personal communication).  However, 
new legislation may be necessary to establish the legality of EPT, as undertaken recently in 
California and Tennessee63,64 and currently under consideration elsewhere.  Pharmacy laws 
may also influence the utilization of EPT.  For example, legislation to regulate or curtail 
online access to prescription drugs may unwittingly place limits on EPT. 
Adverse Effects of Antimicrobial Therapy 
Although individualized use of EPT for selected STDs apparently has been common for 
many years, systematic use as a public health recommendation represents a new paradigm 
for STD prevention. The risk of serious adverse intolerance, toxicity, or allergic reactions 
is low for the regimens recommended for treatment of gonorrhea and chlamydial infections, 
and for the drugs that might be contemplated for treatment of other STDs.  However, even 
low risk may influence the acceptance of EPT as a routine procedure by some providers, 
health maintenance organizations, and public health agencies, largely because of the 
possible medicolegal implications of adverse events.  Development and implementation of 
guidelines by public health agencies, professional societies, and health care institutions 
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should influence community standards of clinical care and help to reduce such risks or 
providers’ perceptions of the risks. The success of EPT as an STD prevention strategy also 
will depend in part on the development and implementation of methods to reduce the risk of 
adverse effects. Therefore, EPT should routinely be accompanied by information that 
warns potentially allergic recipients to defer treatment and seek medical attention, and 
advises partners of the potential side effects of therapy and sources of care in the event of 
adverse events.  At the same time, the likely population-level benefits of improved STD 
partner management dictate that the risk of adverse events should not in itself preclude use 
of EPT. 
Research Agenda 
Review of the available data on EPT revealed numerous gaps in knowledge that must be 
filled to optimize recommendations and implementation of EPT as a routine partner 
management strategy.  The following list is not comprehensive, and the sequence does not 
denote priority. Each of the implementation issues implies one or more research needs, as 
do all the limitations of the existing data cited above. 
Therapeutic Efficacy of Regimens Employed for EPT 
Systematic research is indicated to confirm and explain the observation of higher-than-
expected rates of persistent C. trachomatis infection in women. Studies should include 
extended follow-up of treated patients, treatment with alternate antibiotics, variable 
regimens of azithromycin and perhaps doxycycline, and associated laboratory-based 
research. Research also is indicated to elucidate the possible contribution of suboptimal 
efficacy of single-dose treatment recommendations for trichomoniasis as a factor that may 
have contributed to the apparent failure of EPT in one trial to modify the frequency of 
persistent or recurrent infection.  Scant data document the efficacy of single-dose 
metronidazole against trichomoniasis in men, and no studies of therapeutic efficacy in men 
have used sensitive diagnostic methods, such as PCR, to document cure.  Knowledge of the 
efficacy of the regimens recommended for uncomplicated gonorrhea and chlamydial 
infection against subclinical or incipient PID would inform strategies to help prevent PID 
and its complications in the female recipients of EPT.   
Organization and Systems for EPT 
EPT will continue to be employed by individual practitioners and clinics, but optimal use to 
maximize prevention efficacy will require coordinated, systematic approaches involving the 
public health sector, private sector clinicians and agencies, pharmacies, health insurers, and 
community-based organizations.  Organization of such collaborative efforts is the logical 
domain of state and local health departments.  Research is indicated into systematic 
approaches and organization, including expanded cost effectiveness research.  Such a study 
is soon to be initiated in Washington State (Golden MR, personal communication).  
Therapeutic Compliance 
Research is indicated on compliance with various models of EPT, including patient delivery 
of drugs, patient delivery of prescriptions, treatment by public health personnel away from 
clinical facilities, pharmacy-facilitated treatment and, for each of these circumstances, the 
influence of direct observation of treatment by the index patient, pharmacist or other 
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provider. Although most EPT probably will be accomplished primarily with single-dose 
regimens, compliance with multiple-dose regimens (e.g., doxycycline for chlamydial 
infection) also is of interest. 
EPT for Trichomoniasis 
Despite the challenges to successful and safe EPT in partner management for women with 
trichomoniasis, it is likely that many providers will continue to employ the practice, and 
further research on the efficacy of EPT is a high priority.  Studies should include 
confirmation of the efficacy of single-dose and short-course therapy with metronidazole or 
tinidazole in women with vaginal trichomoniasis, as well as assessment of co-morbidities, 
and should be conducted in broadly representative populations.  Expanded information is 
needed on the efficacy of single-dose metronidazole or tinidazole against T. vaginalis 
infection or carriage in men. 
EPT for Etiologically Undefined STDs 
Study is indicated on use of EPT for partners of patients with NGU, MPC, PID and perhaps 
scabies and pediculosis pubis. An important component will include qualitative research 
among health care providers and patients about the role and implementation of EPT in 
persons with NGU or cervicitis in the absence of diagnostic tests for N. gonorrhoeae and C. 
trachomatis, or while awaiting the results of such tests.  In some settings, studies are 
indicated for use of EPT in chancroid, although this presently is a low priority in the U.S.  
Behavioral Research and Surrogate Markers of EPT Success 
Substantial behavioral research is indicated to enhance the efficacy and evaluate the 
performance of EPT as a partner management strategy.  Currently available data 
demonstrate the value of behavioral outcomes and suggest that behavioral markers, perhaps 
especially those in the causal pathway that results in reduced prevalence of infection at 
follow-up, might serve as surrogates for prediction of rates of index case reinfection, 
facilitating the design of future trials with shorter follow-up and at considerably less 
expense than studies dependent on biomedical outcomes.  Future behavioral research also 
should address the association of various partner management strategies with resumption of 
sex with treated versus untreated partners, with new partners, and with condom use. 
Additional Populations 
The high rates and potentially serious consequences of gonorrhea and chlamydial infection 
in teens <18 years old, pregnant women, and MSM dictate the need for studies of EPT 
implementation and outcomes in these populations.  Studies among MSM may be a 
particularly high priority, in view of resurgent sexual risks and STD rates and the poor 
outcomes of standard partner management practices.  Research in MSM should incorporate 
methods to assess the prevalence of previously undiagnosed HIV infection in the recipients 
of EPT and the response to accompanying advice to seek health care, including HIV testing 
and counseling. 
STD Co-morbidity in Recipients of EPT 
The available data on co-morbidity in the sex partners of infected patients were derived 
from retrospective analysis of patients attending STD clinics with self-described STD 
exposures. Studies of partners who are offered EPT are indicated to determine the 
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prevalences of the index STD, other STDs, and other co-morbidities. A particularly high 
priority is to elucidate the prevalence of overt PID, and ideally of subclinical salpingitis, in 
female recipients of EPT for chlamydial infection or gonorrhea.  Information also is 
desirable on non-STD co-morbidities, such as substance abuse and psychological 
impairment. 
Development of Patient Education Materials and Counseling Strategies 
Systematic research is needed on the formulation and context of written materials to 
accompany EPT, counseling strategies to enhance communication between index cases 
with their partners, and the roles of ancillary health personnel and agencies, such as 
pharmacies and community based organizations.  Such research should emphasize not only 
the development of such counseling and educational materials, but the recipients’ 
immediate and long-term behavioral responses to them. 
Effect of EPT on Health Care-seeking Behavior 
Studies are indicated to determine the compliance of intended recipients of EPT with 
treatment and to accompanying advice to seek health care.  There should be particular 
emphasis on women, especially those with symptoms consistent with salpingitis, but such 
knowledge is needed for the entire range of intended recipients, including heterosexual 
men, MSM, teens, and women with and without symptoms of complicated infection. 
Health Care Providers’ Perceptions, Beliefs, and Attitudes 
Although several recent surveys document considerable use of EPT by some providers, no 
systematic data have addressed the determinants of providers’ decisions about EPT or other 
partner management strategies.  Similarly, providers’ beliefs about what partner services 
are and are not offered by their local or state health departments might influence their 
utilization of EPT and the development of local policies, strategies, and options. 
Other Research Issues 
Most of the EPT implementation issues carry their own implications for research.  For 
example, the only available data on the legality of EPT is based on the personal opinions of 
survey respondents, and refinement is desirable.  The frequency of adverse drug effects in 
recipients of EPT may be worthy of formal study.  Systematic understanding of the 
attitudes and responses of health insurers would facilitate implementation.  Assessment of 
programs’ responses to the cost of EPT, and other experiences in implementation, will 
inform program development in other jurisdictions.  Further research is needed to determine 
optimal packaging of drugs and counseling materials, and qualitative research is indicated 
to assess providers’ and health agencies’ attitudes, beliefs and practices with respect to EPT 




Three RCTs available for analysis and other supporting data indicate that EPT is a useful 
option to facilitate partner management in heterosexual men and women with chlamydial 
infection or gonorrhea. This support derives from documented prevention of persistent or 
recurrent infection one month to 4 months after treatment, and from favorable associations 
of EPT with the study subjects’ reported success in notifying their partners, beliefs that 
their partners were treated, and reductions in post-treatment sexual behaviors that risk 
reinfection. Reducing reinfection is particularly important in women because of the risk of 
PID and its sequelae, and serious outcomes of chlamydial infection and gonorrhea are 
uncommon in men.  Thus, from a clinical perspective, preventing reinfection may be less 
important in men than women.  However, at a population level men generally are more 
efficient STD transmitters than women, and preventing recurrent infections in men may be 
important in reducing continued transmission in the community. 
Ongoing assessment will be needed to evaluate all partner management strategies.  
However, the available evidence indicates that EPT is at least equivalent in efficacy to 
standard partner management for gonorrhea and chlamydial infection; that traditional 
partner management by public health agencies and health care providers for these STDs is 
limited in scope; and that the benefits of EPT outweigh the risks.  Therefore, EPT should be 
available to clinicians as an option for partner management for gonorrhea and chlamydial 
infection. EPT represents an additional strategy for partner management of persons with 
gonorrhea or chlamydial infection that does not replace other strategies such as standard 
patient referral and provider-assisted partner referral, when available.  Along with 
medication, recipients of EPT should also receive written advice (and, when possible, 
personal counseling, such as by a pharmacist) that clinical evaluation is desirable in 
addition to EPT. This is particularly important when EPT is provided for female partners 
and for male partners with symptoms.  EPT also should be accompanied by information 
warning recipients not to accept treatment if allergic to the drug or to related compounds, 
and about common side effects and the appropriate responses to them. 
At present, recommendations to employ EPT are not feasible in many settings because of 
pragmatic issues in implementation, including the uncertain legal status of EPT in some 
states. The legal and other barriers to implementation of EPT will need to be addressed and 
resolved at the local or state level by collaboration between individuals, local and state 
health departments, and other organizations interested in STD prevention.  Substantial 
operational research is indicated to optimize the use of EPT. 
The available data do not support routine employment of EPT in the management of 
women with trichomoniasis, despite its historically frequent use.  However, only a single 
trial of modest size and uncertain generalizability has been conducted.  Drug intolerance 
may be more frequent in treating trichomoniasis than with the regimens used for gonorrhea 
or chlamydial infection, and STD co-morbidities are especially prevalent in persons with 
trichomoniasis, further challenging the utility of EPT.  Therefore, pending additional data, 
EPT should be used with caution in managing women with trichomoniasis, but it should 
remain an option when treatment of partners cannot otherwise be assured. 
No data support the use of EPT in the routine management of syphilis, which typically 
requires injection therapy and for which direct assistance with partner management is 
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generally available from local or state public health departments.  No available data address 
the efficacy or role of EPT in the management of any STD in MSM, many of whose 
partners are likely to have undiagnosed HIV infection or other STDs.  Experience also is 
lacking in the use of EPT in the management of patients with etiologically undefined 
clinical syndromes such as NGU, MPC, and PID. 
The available RCTs reinforce existing recommendations for retesting women with 
chlamydial infection approximately 3 months after treatment, and provide support for 
extension of routine retesting to men following chlamydial infection and to both men and 
women with gonorrhea. 
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GUIDANCE FOR USE OF EXPEDITED PARTNER THERAPY

EPT is at least equivalent to patient referral in preventing persistent or recurrent gonorrhea 
or chlamydial infection in heterosexual men and women, and in its association with several 
desirable behavioral outcomes.  These conclusions support the following recommendations:  
•	 Gonorrhea and chlamydial infection in women:  EPT can be used to treat 
partners as an option when other management strategies are impractical or 
unsuccessful. Symptomatic male partners should be encouraged to seek medical 
attention, in addition to accepting therapy by EPT, through counseling of the index 
case, written materials, and/or personal counseling by a pharmacist or other 
personnel. 
•	 Gonorrhea and chlamydial infection in men:  EPT can be used to treat partners as 
an option when other management strategies are impractical or unsuccessful.  
Female recipients of EPT should be strongly encouraged to seek medical attention, 
in addition to accepting therapy. This should be accomplished through written 
materials that accompany medication, by counseling of the index case and, when 
practical, through personal counseling by a pharmacist or other personnel.  It is 
particularly important that female recipients of EPT who have symptoms that 
suggest acute PID, such as abdominal or pelvic pain, seek medical attention.   
•	 Gonorrhea and chlamydial infection in men who have sex with men:  EPT 
should not be considered a routine partner management strategy, because data are 
lacking on the efficacy in this population, and because of a high risk of co-
morbidity, especially undiagnosed HIV infection, in partners.  EPT should only be 
used selectively, and with caution, when other partner management strategies are 
impractical or unsuccessful. 
•	 Women with trichomoniasis:  EPT is not recommended for routine use in the 
management of women with trichomoniasis, because of a high risk of STD co-
morbidity in partners, especially gonorrhea and chlamydial infection.  EPT should 
only be used selectively, and with caution, when other partner management 
strategies are impractical or unsuccessful. 
•	 Syphilis:  EPT is not recommended for routine use in the management of patients 




1.	 Parran T.  Shadow on the Land:  Syphilis.  New York: Reynal & Hitchcock, 1937. 
2.	 CDC. Program operations guidance: Partner services.  Department of Health and Human Services, 
Atlanta, GA, 2000. 
3.	 CDC. HIV partner counseling and referral services: Guidance. Department of Health and Human 
Services, Atlanta, GA 1998. 
4.	 Oxman A, Scott EAF, Sellors JW, et al.  Partner notification for sexually transmitted diseases: An 
overview of the evidence.  Can J Public Health  1994;85(Suppl 1):S41-7. 
5.	 Macke BA, Maher JE.  Partner notification in the United States: An evidence-based review. Am J 
Prev Med 1999;17:230-42. 
6.	 Mathews C, Coetzee N, Zwarenstein M, et al.  A systematic review of strategies for partner 
notification for sexually transmitted diseases, including HIV/AIDS.  Int J STD AIDS 2002;13:285-
300. 
7.	 Peterman TA, Toomey KE, Dicker L, et al.  Partner notification for syphilis: A randomized, 
controlled trial of three approaches.  Sex Transm Dis 1997;24:511-21. 
8.	 Potterat JJ, Muth SQ, Rothenberg RB, et al.  Sexual network structure as an indicator of epidemic 
phase.  Sex Transm Inf  2002;78(Suppl 1):i52-8. 
9.	 Wiley JL, Jolly A.  Patterns of chlamydia and gonorrhea infection in sexual networks in Manitoba, 
Canada.  Sex Transm Dis 2001;28:14-24. 
10.	 Rothenberg R, Kimbrough L, Lewis-Hardy R, et al.  Social network methods for endemic foci of 
syphilis: A pilot project. Sex Transm Dis  2000;27:12-18.  
11.	 Brackbill R, Sternberg M, Fishbein M.  Where do people go for treatment of sexually transmitted 
diseases? Fam Plann Perspect  1999;31:10-15. 
12.	 Golden MR, Hogben M, Handsfield HH, et al.  Partner notification for HIV and STD in the United 
States:  Low coverage for gonorrhea, chlamydial infection and HIV.  Sex Transm Dis 2003;30:490-
6. 
13.	 Golden MR, Hogben M, Potterat J, et al.  HIV partner notification in the United States: A national 
survey of program coverage and outcomes.  Sex Transm Dis 2004;31:709-12. 
14.	 Eng TR, Butler WT (eds.).  The hidden epidemic: Confronting sexually transmitted diseases.  
Washington, DC: National Academy Press, 1997. 
15.	 St. Lawrence JS, Montano DE, Kasprzyk D, et al.  STD screening, testing, case reporting and clinical 
and partner notification practices: A national survey of US physicians. Am J Public Health 
2002;92:1784-8. 
16.	 Hogben M, St. Lawrence JS, Montano DE, et al.  Physicians’ opinions about partner notification 
methods: Case reporting, patient referral, and provider referral.  Sex Transm Inf 2004;80:30-4. 
17.	 Golden MR, Whittington WL, Gorbach PM, et al. Partner notification for chlamydial infections 
among private sector clinicians in Seattle-King County: A clinician and patient survey. Sex Transm 
Dis 1999;26:543-7. 
18.	 Potterat JJ, Rothenberg R. The case-finding effectiveness of self-referral system for gonorrhea: a 
preliminary report. Am J Public Health 1977;67:174-6. 
19.	 Woodhouse DE, Potterat JJ, Muth JB, Pratts CI, Rothenberg RB, Fogle JS. A civilian-military 
partnership to reduce the incidence of gonorrhea. Public Health Rep 1985;100:61-5. 
35 

20.	 Patel HC, Viswalingam ND, Goh BT. Chlamydial ocular infection: Efficacy of partner notification 
by patient referral. Int J STD AIDS 1994;5:244-7. 
21.	 van de Laar MJ, Termorshuizen F, van den Hoek A. Partner referral by patients with gonorrhea and 
chlamydial infection. Case-finding observations. Sex Transm Dis 1997;24:334-42. 
22.	 Chacko MR, Smith PB, Kozinetz CA. Understanding partner notification (Patient self-referral 
method) by young women. J Pediatr Adolesc Gynecol 2000;13:27-32. 
23.	 Golden MR, Whittington WLM, Handsfield HH, et al.  Partner management for gonococcal and 
chlamydial infection: Expansion of public health services to the private sector and expedited sex 
partner treatment through a partnership with commercial pharmacies.  Sex Transm Dis 2001;26:658-
65. 
24.	 Fortenberry JD, Brizendine EJ, Katz BP, Orr DP. The role of self-efficacy and relationship quality in 
partner notification by adolescents with sexually transmitted infections. Arch Pediatric Adol Med 
2002;156:1133-7. 
25.	 Hogben M, McCree DH, Golden MR.  Patient-delivered partner therapy for sexually transmitted 
diseases as practiced by U.S. physicians. Sex Transm Dis 2005;32:101-5. 
26.	 Niccolai LM, Winston DM.  Physicians’ opinions on partner management for nonviral sexually 
transmitted infections.  Am J Prev Med 2005;28:229-33. 
27.	 Packel L, Guerry S, Bauer H, et al.  Patient-delivered partner therapy for chlamydial infections: 
attitudes and practices of California physicians and nurse practitioners. Sex Transm Dis, in press. 
28.	 Rogers M, Schillinger JA, Opdyke KM, et al.  A comparison of standard partner management 
strategies with patient-delivered partner therapy employed by physicians and mid-level providers in 
New York City.  International Society for STD Research, 16th Meeting. Amsterdam, The 
Netherlands, July 10 – 13, 2005. 
29.	 Ramstedt K, Forssman L, Johannisson G.  Contact tracing in the control of genital Chlamydia 
trachomatis infection.  Int J STD AIDS 1991;2:116-8. 
30.	 Kissinger P, Brown R, Reed K, et al.  Effectiveness of patient-delivered partner medication for 
preventing recurrent Chlamydia trachomatis. Sex Transm Inf 1998;74:331-3. 
31.	 Nuwaha F, Kambugu F, Nsubuga PSJ, et al.  Efficacy of patient-delivered partner medication in the 
treatment of sexual partners in Uganda. Sex Transm Dis 2001;28:105-10. 
32.	 Schillinger JA, Kissinger P, Calvet H, et al. Patient-delivered partner treatment with azithromycin to 
prevent repeated Chlamydia trachomatis infection among women.  Sex Transm Dis 2003;30:49-56. 
33.	 Golden MR, Whittington WLH, Handsfield HH, et al.  Effect of expedited treatment of sex partners 
on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med  2005;352:676-85. 
34.	 Kissinger P, Mohammed H, Richardson-Alston G, et al.  Patient-delivered partner treatment for male 
urethritis: A randomized controlled trial.  Clin Infect Dis 2005;41:623-9. 
35.	 Kissinger P, Schmidt N, Mohammed H, et al. Patient-delivered partner treatment for female 
trichomoniasis: a randomized controlled trial.  Sex Transm Dis, in press. 
36.	 Schillinger JA, Sternberg MR, Gift TL.  Cost effectiveness of patient-delivered partner treatment 
compared to partner referral for chlamydial infections in women.  National STD Prevention 
Conference, San Diego, CA, March 4 – 7, 2002. 
37.	 Gift TL, Farley TA, Leichliter JS, et al.  The cost effectiveness of patient-delivered partner treatment 
(PDPT) for female partners of men with urethritis compared to two alternatives.  International 
Society for STD Research, 16th Meeting.  Amsterdam, The Netherlands, July 10 – 13, 2005. 
38.	 Fenton K, Imrie J.  Increasing rates of sexually transmitted diseases in homosexual men in western 
Europe and the United States: Why? Infect Dis Clin North Am 2005;19:311-31. 
36 

39.	 Lindberg CE. Primary care management of sexually transmitted urethritis in adolescent males.  J Am 
Acad Nurse Practitioners 2003;15:156-64. 
40.	 Novick LF, Teran S, Dolbear G.  Sexually transmitted disease in adolescents. Am J Prev Med 
2003;24(Suppl 4):133-8. 
41.	 Centers for Disease Control and Prevention.  Sexually transmitted diseases surveillance, 2003.  
Atlanta, GA: Department of Health and Human Services, 2004. 
42.	 Hook EW 3rd, Stephens J, Ennis DM. Azithromycin compared with penicillin G benzathine for 
treatment of incubating syphilis.  Ann Intern Med 1999;21:434-7. 
43.	 Hook EW 3rd, Martin DH, Stephens J, Smith BS, Smith K.  A randomized, comparative pilot study of 
azithromycin versus benzathine penicillin G for treatment of early syphilis. Sex Transm Dis 
2002;29:486-90. 
44.	 Tun W, Walsh C, Siller J, et al.  Acceptance of patient-delivered partner-therapy for syphilis among 
men who have sex with men (MSM), San Francisco, CA.  National STD Prevention Conference, 
Philadelphia, PA, March 8 – 11, 2004. 
45.	 Centers for Disease Control and Prevention.  Brief report: Azithromycin treatment failures in syphilis 
infections – San Francisco, California, 2002 – 2003.  Morbid Mortal Weekly Rep  2004;53:197-9.  
46.	 Lukehart S, Godomes C, Molini BG, et al. Macrolide resistance in Treponema pallidum in the United 
States and Ireland. N Engl J Med 2004;351:154-8. 
47.	 Stekler J, Bachmann L, Brotman RM, et al. Concurrent sexually transmitted infections in sex 
partners of index patients with bacterial STIs: Implications for patient-delivered partner therapy.  
Clin Infect Dis 2005;40:787-93. 
48.	 IMS, Inc.  Leading 20 therapeutic classes by total U.S. dispensed prescriptions, 2004. 
http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_49695974_68914714,00.html. 
(Accessed 29 June, 2005) 
49.	 McCree DH, Oh J, Hogben M.  The role of pharmacists in patient-delivered partner therapy. Am J 
Health-Systems Pharm 2005;62:643-6. 
50.	 Golden MR, Anukam U, Williams DH, et al.  The legal status of patient-delivered partner therapy for 
sexually transmitted infections in the United States.  Sex Transm Dis 2005;32:112-4. 
51.	 Klausner JD, Chaw JK.  Patient-delivered therapy for chlamydia: Putting research into practice.  Sex 
Transm Dis 2003;30:509-11. 
52.	 Erbelding EJ, Zenilman JM.  Toward better control of sexually transmitted diseases. N Engl J Med 
2005;352:720-1. 
53.	 Whittington WLW, Kent C, Kissinger P, et al. Determinants of persistent and recurrent Chlamydia 
trachomatis infection in young women: results of a multicenter cohort study.  Sex Transm Dis 
2001;28:117-23. 
54.	 Centers for Disease Control and Prevention.  Sexually transmitted diseases treatment guidelines, 
2002.  Morbid Mortal Weekly Rep 2002;51(RR-6):1-80. 
55.	 Hu D, Hook EW 3rd, Goldie SJ.  Screening for Chlamydia trachomatis in women 15 to 29 years of 
age: A cost effectiveness analysis.  Ann Int Med 2004;141:501-13. 
56.	 Martin DH, Mroczkowski TF, Dalu ZA, et al.  A controlled trial of a single dose of azithromycin for 
the treatment of chlamydial urethritis and cervicitis.  N Engl J Med 1992;327:921-5. 
57.	 Katz B, Caine VA, Batteiger BE, Jones RB.  A randomized trial to compare 7- and 21-day 
tetracycline regimens in the prevention of recurrence of infection with Chlamydia trachomatis. Sex 
Transm Dis 1991;18:36-40. 
58.	 Forna F, Gulmezoglu AM.  Interventions for treating  trichomoniasis in women. Cochrane Database 
Syst Rev 2003;CD000218.  
37 

59.	 Kawamura N.  Metronidazole and tinidazole in a single large dose for treating urogenital infections 
with Trichomonas vaginalis in men.  Br J Vener Dis 1978;54:81-3. 
60.	 Wendel KA, Erbelding EJ,  Gaydos CA, Rompalo AM.  Trichomonas vaginalis polymerase chain  
reaction compared with standard diagnostic and therapeutic protocols for  detection and treatment of 
trichomoniasis. Clin Infect Dis  2002;35:576-80. 
61.	 Presutti Laboratories, LLC, Rolling Meadows, IL. Data on file (FDA submission package; Dawn 
Flynn, personal communication).  (www.presuttilabs.com.) 
62.	 Khan A, Fortenberry JD, Juliar BE, et al.  The prevalence of chlamydia, gonorrhea, and trichomonas 
in sexual partnerships: Implications for partner notification and treatment. Sex Transm Dis 
2005;32:260-4. 
63.	 Tennessee Department of Health. Patient Delivered Therapy: An Additional Means for Addressing 
the Chlamydia Trachomatis Problem. http://www2.state.tn.us/health/CEDS/STD/filed.htm (accessed 
February 2005). 
64.	 California Department of Health Services STD Control Branch. Patient-delivered therapy of 





Outcomes of Partner Notification for Gonorrhea and Chlamydial Infection by Patient 
Referral 
Location (year) Number Index 
Patients Studied 
STI % Partners 
Treated 




93 GC 54 All patients received a routine follow-
up call.  Partner treatment status based 
on confirmed treatment in STD clinic 
Colorado Springs 
(1985)19 
975 GC 29 “Perfunctory” PN interviewing 
performed with no follow-up.  Partner 
treatment status based on confirmed 
treatment or evaluation 
London (1994)20 254 CT 53 Index patients had ocular CT infection.  
Treatment status based on confirmed 
treatment. 
Amsterdam (1997)21 440 GC/CT 49 Patients given referral cards. Partner 
treatment status based on confirmed 
treatment in STD clinic or elsewhere 
Houston (2000)22 54 GC/CT 55 Partner treatment status based on index 
patient report. Percentage reflects any 
partner having been treated 






59 Partner notification status based on 
index patient report (treatment outcome 
not reported) 
GC=gonorrhea, CT=C. trachomatis, NGU=nongonococcal urethritis, TV=trichomoniasis. 
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Table 2 
Randomized Controlled Trials in the United States:  Persistent/Recurrent Infection 
Trial Setting and Study 
Population 
Study Design Intervention and Control Persistent/Recurrent Infection 
Rate 
CDC Project 455, B2 • Multi-center (6 cities) • Uncomplicated CT • PDPT to maximum 4 • Control  108/726 (14.9%) 
Schillinger et al. Sex 
Transm Dis 2003;30:49-56 
• 1996- 2000 
• N=1,787, 81% followed 
• Women age 14-34 
• Primary care, FP, teen, 
(without GC) 
• 1.0g azithromycin DOT 
• 21 days – 3 months 
• Urine PCR/LCR 
partners 
• Control = patient-referral 
(verbal and written) 
• EPT 87/728 (12.0%) 
OR = 0.80 (0.62 – 1.05) 
�2 = 2.67, p = .102 
STD, ED 
Seattle  
Golden et al. NEJM 
2005;.352:676-685. 
• Seattle-King Co., WA 
• 1998 - 2003 
• N=2,751, 68% follow-up 
• Male 23%, Female 77%, 
age >14 yr (mean 23 yr) 
• All reporting sites: STD, 
FP, private, ED 
• Uncomplicated CT 
(N=2162), GC (450), or 
both (139) 
• AZM 1.0 g + CFX 400 
mg for CT, GC 
• Follow-up 3-19 wk 
• Urine NAAT (LCR or 
TMA) 
• Patient or partner pick-up 
of drug at 1 of 12 
pharmacies 
• Control = patient-referral  
• DIS assistance (both 
arms) if patient 
unable/unwilling to 
contact partner 
• Control  121/931 (13.0%) 
• EPT 92/929 (9.9%) 
RR = 0.76 (0.59 – 0.98) 
�2 = 4.39, p = .04 
See supplemental tables for separate 
CT/GC outcomes 
New Orleans Urethritis 
Trial 
Kissinger et al. Clin Inf 
Dis 2005;41:623-9. 
• New Orleans, LA 
• 2002 - 2004 
• N=629, 80% behavioral 
FU, 30% biological FU 
• Male age >16, median 24 
• Symptomatic urethritis 
(61% GC, 21% CT, 6% 
both) 
• AZM 1.0 g + CFX 
400mg or cipro 500 mg 
• PDPT 
• Control = patient-referral 
with brief counseling 
• Third arm “Booklet 
Referral” 
• Control  35/82  (43%) 
• EPT 20/87  (23%) 
• Booklet 16/112 (14%) 
EPT v control: 
yr • GenProbe(enrollment) OR  = 0.38 (0.19 – 0.74) 
• STD clinic Urine PCR (follow-up) BEPR v control: 





Kissinger et al. Sex 
Transm Dis In press. 
• New Orleans, LA 
• 2001 – 2004 
• N=282, 87% behavioral 
FU, 80% biological 
• Women age 16-44 yr 
• STD clinic 
• Trichomonal vaginitis 
• Metronidazole 2.0 g 
• Follow-up 21-56 d 
• Wet mount at 
enrollment, culture 
(InPouch) at follow-up 
• PDPT to maximum 4 
partners 
• Control = patient-referral 
with brief counseling 
• Third arm “Booklet 
Referral” 
• Control = 7/111 = 6.3% 
• EPT = 11/114 = 9.6% 
• Booklet = 11/122 (9.0%) 
EPT v control: 
OR  = 1.58 (0.61 – 4.12) 
BEPR v control: 






Persistent or Recurrent Gonorrhea and Chlamydial Infection in the Seattle RCT 
Index Case Dx EPT (%) Standard (%) RR (95% CI) 
GC or CT 92/929 (10) 121/931 (13) 0.76 (0.59 – 0.98) 
Male 13/194 (7) 24/202  (12) 0.56 (0.30 – 1.08) 
Female 79/735 (11) 97/729  (13) 0.81 (0.61 – 1.07) 
Gonorrhea 6/179  (3) 19/179  (11) 0.32 (0.13 – 0.77) 
Male 3/72 (4) 8/85 (9) 0.44 (0.12 – 1.61) 
Female 3/107  (3) 11/94  (12) 0.25 (0.07 – 0.83) 
Chlamydial Inf. 86/797 (11) 105/798 (13) 0.82 (0.62 – 1.07) 
Male 10/132 (8) 17/135  (13) 0.60 (0.29 – 1.27) 
Female  76/665 (11) 88/663  (13) 0.86 (0.65 – 1.15) 
Note. Table is a reproduction from Golden et al. NEJM  2005;352:676-685, with 




Demographic, clinical and behavioral factors associated with persistent or 
recurrent gonorrhea or chlamydial infection 




< 20 109 (15) 0.7 (0.6-0.8) 0.8 (0.7-0.9) 
   20-24 68 (11) per category change per category change 
   24-29 22 (9) 
30+ 14 (6) 
Gender: 
Male 37 (9) 0.8 (0.6-1.1) 
  Female 176 (12) 
Initial diagnosis: 
  Gonorrhea only 15 (6) 1.0 1.0 
  Chlamydial infection only 175 (12) 2.1 (1.2-3.4) 1.7 (0.9-2.9) 
  Both gonorrhea & 23 (24) 4.3 (2.4-7.9) 3.4 (1.8-6.4) 
    chlamydial infection 
Source of STI diagnosis: 
STD clinic 33 (10) 1.1 (0.7-1.6) 
Other public health clinic 73 (17) 1.8 (1.3-2.5) 1.4 (1.1-1.9) 
  Emergency room 22 (11) 1.2 (0.8-2.0) 
  Community Clinic 27 (11) 1.2 (0.8-1.8) 
Other 58 (9) 1.0 
Race/ethnicity:  
White 93 (11) 0.9 (0.7-1.2) 
Black race 75 (12) 1.1 (0.8-1.4) 
   Native American /  10 (9) 0.8 (0.4-1.5) 
        Alaskan Native 
Asian / Hawaiian / 34 (14) 1.3 (0.9-1.8) 
Pacific Islander 
Other race 12 (13) 1.2 (0.7-1.2) 
Hispanic 13 (7) 0.6 (0.4-1.1) 0.5 (0.3-1.0) 
Number of sex partners at 
baseline (last 60 days) 
0-1 126 (11) 1.0 
2 56 (12) 1.1 (0.8-1.5) 
3+ 31 (16) 1.5 (0.9-1.9) 
Any sex since treatment 
Yes 182 (13) 2.2 (1.5-3.4) 1.9 (1.1-3.2) 
No 22 (6) 
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New sex partner since 
treatment**  
Yes 70 (14) 1.2 (0.9-1.6) 
No 112 (12) 
Number of sex partners since 
treatment with whom condom 
not used for all vaginal sex 
0 66 (8) 1.7 (1.4-2.2) 1.5 (1.2-2.0) 
1 122 (14) per category change per category change 
2+ 14 (20) 
Reexposure to sex partner 
patient believes had other 
partners 
Yes 73 (14) 1.4 (1.1-1.8) 
No 130 (10) 
Sex with any partner not 
believed to be “very likely” 
treated or tested STI negative 
Yes 40 (25) 2.6 (1.9-3.5) † 
No 156 (10) 
All partners “very likely” 
treated or tested STI negative 
Yes 87 (9) 0.7 (0.5-0.9) † 
No 106 (14) 
Study arm
   Expedited partner treatment 92 (10) 0.8 (0.6-1.0) 0.7 (0.6-1.0) 
   Standard partner care 121 (13) 
Rates of recurrent chlamydial infection did not differ between index patients treated with 
azithromycin (13%) and those treated with doxycycline (11%) (RR=1.2 95% CI 0.8-1.6). 
* Persistent or recurrent infection defined as chlamydial infection at follow-up in persons originally 
diagnosed with chlamydial infections, gonorrhea in those originally diagnosed with gonorrhea, or 
either infection in those originally diagnosed with both pathogens. 
**Excludes those with no sex partners since treatment 
†Variable statistically significant in multivariate model. Inclusion in model results in study randomization 
assignment not being significantly associated with persistent or recurrent infection.  These variables were not 
included in the final multivariate model because of their role in the presumed causal pathway between the 
trial’s intervention and the outcome of persistent or recurrent STI.  RRs for multivariate model generated via 
generalized linear model with binary outcomes and log link 
Note.  Table is a reproduction from Golden et al.  NEJM  2005;352;676-685, with permission from the New 






Variations in Sex Partner Notification as a Function of EPT versus Control Condition among RCTs 
Notification Behavior EPT Control  RR (95% CI) P 
6-city trial 
Talked to partner and delivered fact sheet (and medications in EPT) 85% 75% 1.14 (1.08 – 1.21) .01 
Seattle trial 
Notified partner of exposure or knew of negative test 77% 78%  0.92 (0.77 – 1.10) ns 
New Orleans (urethritis)1 
Talked to partner about infection 71% 48%  -- .001 
Gave intervention to partner 70% 48%  -- .001 
New Orleans (trichomoniasis)1 
Talked to partner about infection 90% 88%  -- ns 
Gave intervention to partner 82% 88%  -- ns 





Variations in Sex Partner Treatment as a Function of EPT versus Control Condition 
Treatment Behavior  EPT Control  RR (95% CI) P 
6-city trial 
Reported “very likely” partner took medication1  86% 57%  1.50 (1.40 – 1.59) .001 
Seattle trial 
Reported all partners “very likely treated” or tested negative 61% 49% 1.25 (1.14 – 1.36) .001 
Reported partner “very likely” treated or tested negative 64% 52% 1.19 (1.12 – 1.27) .001 
New Orleans (urethritis)2 
Reported seeing patient take medication 48% 26%  -- .001 
Partner reported taking medication 56% 34%  -- .001 
Checked partner was treated 64% 42%  -- .001 
New Orleans (trichomoniasis)2 
Reported seeing patient take medication 63% 18%  -- .001 
Partner reported taking medication 77% 70%  -- ns 
Checked partner was treated 78% 76%  -- ns 
1Analysis limited to women with one partner.  2Percentages for this study are based on proportion of partnerships, not proportion of cases.  






Variations in Sexual Behaviors as a Function of EPT versus Control Condition 
Sexual Behavior EPT Control  RR (95% CI) P 
6-city trial 
Reported acquisition of new sex partner 23% 28%  0.83 (0.69 – 0.99) .05 
Seattle trial 
Reported sex with an untreated partner 6% 12% 0.47 (0.34 – 0.65) .001 
New Orleans (urethritis) 
Reported unprotected sex before partner took medication1  8% 13%  0.63 (0.40 – 0.99) .05 
Reported unprotected sex with any partner 29% 34% 0.85 (0.66 – 1.10) ns 
New Orleans (trichomoniasis) 
Reported unprotected sex before partner took medication1 8% 5% 1.55 (0.62 – 3.88) ns 
Reported unprotected sex with any partner 26% 13% 1.99 (1.20 – 3.34) .01 
1Percentages for this analysis are based on proportion of partnerships, not proportion of cases.  Significance levels are based on GEE; the effect 







STD in Contacts to GC, CT, NGU, or MPC in Seattle, Baltimore, Birmingham and Denver 
STD   Women  Heterosex. men MSM 
(N = 2507) (N = 3511) (N = 460) 
GC (non-GC 
contacts only) 3.9% 3.1% 6.1% 
PID 3.7% n/a n/a 
New HIV 0 0.2% 5.5% 
Early syphilis 0.1% 0 0.4% 
Trichomoniasis 4.9% n/a n/a 
GC/CT (partners 
of women with TV) 10.3% --
Note. Data drawn from Stekler et al. Clin Inf Dis  2005;40:787-793. 
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Figure 1 




















Note. Data drawn from Hogben, et al.  Sex Transm Dis  2005;32:101-105. 




Chlamydial Reinfection Rates In Sweden By Partner Management Strategy According to 






















1 2 3 4

Note. 	Data are drawn from Ramstedt, et al.  Int J STD AIDS  1991;2:116-118. 
1 = No partner management (N = 372); 2 = Patient couseled to refer partner(s) (N  = 997); 3 

= Patient counseled to refer partner(s), compliance monitored (N = 645); 4 = Patient-





















1 2 3 
% Standard care 
Expedited care 
Note. Data are drawn from Golden, et al.  NEJM  2005;352:676-685. 
1 = GC infections only, P = .02 (N = 358); 2 = CT infections only, P = .17 (N = 1595); 3 = 




Differential Infection at Follow-up Among Women Who Reported any Sex Since Treatment 



















Note. Data are drawn from Golden, et al.  NEJM  2005;352:676-685. 
1 = Expedited care; 2 = Standard care; 3 = Total. 
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